UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Quarterly Period Ended SeptemberJune 30, 20162017

 

ORor

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Transition Period From ____________ to ____________

 

Commission file number File Number: 000-54258

 

TERRA TECH CORP.

(Exact nameName of registrantRegistrant as specifiedSpecified in its charter)Charter)

 

NEVADA

26-3062661

(State or other jurisdictionOther Jurisdiction of incorporationIncorporation or organization)Organization)

(I.R.S. Employer Identification No.)

 

4700 Von Karman, Suite 110

Newport Beach, California 92660

(Address of principal executive offices)

2040 Main Street, Suite 225

Irvine, California

92614

(Address of Principal Executive Offices)

(Zip Code)

 

(855) 447-6967

(Registrant’s telephone number, including area code)

N/A

(Former name, former address, and former fiscal year, if changed since last report)

(Registrant’s Telephone Number, Including Area Code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (section 232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files). Yes x No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”filer,” “smaller reporting company” and “smaller reporting“emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer

¨

Accelerated filer

¨x

Non-accelerated filer

¨

Smaller reporting company

x¨

Emerging growth company

¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

 

As of November 5, 2016,August 4, 2017, there were 521,345,040640,043,036 shares of common stock outstanding, 100 shares of Series A Preferred Stock, convertible at any time into 100 shares of common stock, 37,675,95333,146,112 shares of Series B Preferred Stock, convertible into approximately 202,859,596178,469,458 shares of common stock, 14,20,26515,668,298 shares of common stock issuable upon the exercise of all of our outstanding warrants, and 2,233,3334,744,687 shares of common stock issuable upon the exercise of all vested stock options.

 

 
 
 

TERRA TECH CORP. AND SUBSIDIARIES

FORM 10-Q

QUARTERLY PERIOD ENDED JUNE 30, 2017

INDEX

 

 

Page

 

PART I — FINANCIAL INFORMATION

 

Item 1.

Financial Statements

 

Condensed Consolidated Balance Sheets as of June 30, 2017 (Unaudited) and December 31, 2016

 

3

 

Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2017 and 2016 (Unaudited)

 

4

 

Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2017 and 2016 (Unaudited)

 

5

 

Notes to CondensedUnaudited Consolidated Financial Statements (Unaudited)for the Three and Six Months Ended June 30, 2017 and 2016

 

6

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

3426

 

Company Overview

 

3426

 

Results of Operations

 

3634

 

Disclosure About Off-Balance Sheet Arrangements

 

3938

 

Critical Accounting Policies and Estimates

 

3938

 

Liquidity and Capital Resources

 

4038

 

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

 

4140

 

Item 4.

Controls and Procedures

 

4140

 

PART II — OTHER INFORMATION

 

Item 1.

Legal Proceedings

 

4241

 

Item 1A.

Risk Factors

 

4241

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

 

4241

 

Item 3.

Defaults Upon Senior Securities

 

4241

 

Item 4.

Mine Safety Disclosures

 

4241

 

Item 5.

Other Information

 

4241

 

Item 6.

Exhibits

 

4342

 

Signatures

 

4443


 
2
Table of Contents

 

TERRA TECH CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

 

 

June 30,

 

December 31,

 

 

2017

 

 

2016

 

 

September 30,
2016

 

December 31,
2015

 

 

(Unaudited)

 

 

 

 

(Unaudited)

 

(Audited)

 

 

 

 

 

 

ASSETS

ASSETS

ASSETS

 

 

 

 

 

 

 

 

 

 

Current Assets:

 

 

 

 

 

 

 

 

 

 

Cash

 

$3,397,317

 

$418,082

 

 

$9,131,306

 

$9,749,572

 

Accounts Receivable, Net

 

1,072,389

 

741,844

 

Accounts Receivable

 

784,071

 

747,792

 

Inventory

 

3,233,072

 

1,909,330

 

Prepaid Expenses

 

237,623

 

147,230

 

 

 

1,238,529

 

 

 

704,721

 

Inventory

 

 

2,468,099

 

 

 

949,448

 

 

 

 

 

 

 

 

 

 

 

Total Current Assets

 

7,175,428

 

2,256,604

 

 

 

14,386,978

 

 

 

13,111,415

 

 

 

 

 

 

 

 

 

 

 

Property, Equipment and Leasehold Improvements, Net

 

9,804,904

 

6,694,975

 

 

10,581,265

 

10,464,764

 

Intangible Assets, Net

 

22,768,048

 

23,627,098

 

Goodwill

 

32,296,948

 

-

 

 

28,921,260

 

28,921,260

 

Intangible Assets, Net

 

20,634,410

 

118,932

 

Deposits

 

 

53,543

 

 

 

94,528

 

Other Assets

 

 

221,118

 

 

 

54,193

 

 

 

 

 

 

 

 

 

 

 

TOTAL ASSETS

 

$69,965,233

 

 

$9,165,039

 

 

$76,878,669

 

 

$76,178,730

 

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' EQUITY

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

LIABILITIES AND STOCKHOLDERS’ EQUITY

LIABILITIES:

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

 

 

 

 

 

Accounts Payable and Accrued Expenses

 

$6,386,859

 

$1,119,459

 

 

$3,526,498

 

$2,417,400

 

Derivative Liability

 

6,895,000

 

743,400

 

Derivative Liabilities

 

3,163,000

 

6,987,000

 

Short-Term Debt

 

1,953,687

 

917,363

 

 

575,705

 

564,324

 

Income Taxes Payable

 

 

1,783,731

 

 

 

-

 

 

615,830

 

615,830

 

Contingent Consideration

 

 

 

 

 

12,085,859

 

 

 

 

 

 

 

 

 

 

 

Total Current Liabilities

 

 

17,019,277

 

 

 

2,780,222

 

 

 

7,881,033

 

 

 

22,670,413

 

 

 

 

 

 

 

 

 

 

 

Long-Term Liabilities:

 

 

 

 

 

 

 

 

 

 

Long-Term Debt

 

835,955

 

-

 

 

 

736,290

 

 

 

1,354,352

 

Deferred Tax Liability, Net

 

 

194,900

 

 

 

44,000

 

 

 

 

 

 

 

 

 

 

 

Total Long-Term Liabilities

 

 

1,030,855

 

 

 

44,000

 

 

 

736,290

 

 

 

1,354,352

 

 

 

 

 

 

 

 

 

 

 

Total Liabilities

 

 

18,050,132

 

 

 

2,824,222

 

 

 

8,617,323

 

 

 

24,024,765

 

 

 

 

 

 

 

 

 

 

 

COMMITMENTS AND CONTINGENCIES

 

 

12,655,741

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

STOCKHOLDERS' EQUITY:

 

 

 

 

 

Preferred Stock, Convertible Series A, Par Value $0.001; Authorized and Issued 100 Shares as of September 30, 2016 and December 31, 2015, Respectively

 

-

 

-

 

Preferred Stock, Convertible Series B, Par Value $0.001; Authorized 49,999,900 Shares as of September 30, 2016; Authorized 24,999,900 Shares as of December 31, 2015; Issued and Outstanding 40,382,962 and 16,300,000 as of September 30, 2016 and December 31, 2015, Respectively

 

40,383

 

16,300

 

Common Stock, Par Value $0.001; Authorized 990,000,000 Shares as of September 30, 2016; Authorized 350,000,000 Shares as of December 31, 2015; Issued 473,917,277 and 303,023,744 Shares as of September 30, 2016 and December 31, 2015, Respectively

 

473,917

 

303,024

 

STOCKHOLDERS’ EQUITY:

 

 

 

 

 

Preferred Stock, Convertible Series A, Par Value $0.001:

100 Shares Authorized as of June 30, 2017 and December 31, 2016;
100 Shares Issued and Outstanding as of June 30, 2017 and December 31, 2016

 

 

 

Preferred Stock, Convertible Series B, Par Value $0.001:

49,999,900 Shares Authorized as of June 30, 2017 and December 31, 2016;
33,146,112 and 36,825,953 Shares Issued and Outstanding as of June 30, 2017 and December 31, 2016, respectively

 

33,146

 

36,826

 

Common Stock, Par Value $0.001:

990,000,000 Shares Authorized as of June 30, 2017 and December 31, 2016;
618,667,265 and 553,863,812 Shares Issued and Outstanding as of June 30, 2017 and December 31, 2016, respectively

 

618,667

 

553,864

 

Additional Paid-In Capital

 

99,844,560

 

51,843,071

 

 

152,354,775

 

124,915,182

 

Accumulated Deficit

 

 

(60,600,170)

 

 

(45,952,109)

 

 

(83,436,756)

 

 

(72,870,999)

 

 

 

 

 

 

 

 

 

 

Total Terra Tech Corp. Stockholders' Equity

 

39,758,690

 

6,210,286

 

Total Terra Tech Corp. Stockholders’ Equity

 

69,569,832

 

52,634,873

 

Non-Controlling Interest

 

 

(499,330)

 

 

130,531

 

 

 

(1,308,486)

 

 

(480,908)

 

 

 

 

 

 

 

 

 

 

Total Stockholders' Equity

 

 

39,259,360

 

 

 

6,340,817

 

Total Stockholders’ Equity

 

 

68,261,346

 

 

 

52,153,965

 

 

 

 

 

 

 

 

 

 

 

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

 

$69,965,233

 

 

$9,165,039

 

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

 

$76,878,669

 

 

$76,178,730

 

 

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.


 
3
Table of Contents

 

TERRA TECH CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)(UNAUDITED)

 

 

 

For the Three Months Ended

 

 

For the Nine Months Ended

 

 

 

September 30,

 

 

September 30,

 

 

 

2016

 

 

2015

 

 

2016

 

 

2015

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Revenues

 

$6,950,365

 

 

$2,018,351

 

 

$18,198,441

 

 

$7,805,994

 

Cost of Goods Sold

 

 

5,630,979

 

 

 

1,648,545

 

 

 

15,095,137

 

 

 

6,944,859

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross Profit

 

 

1,319,386

 

 

 

369,806

 

 

 

3,103,304

 

 

 

861,135

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, General and Administrative Expenses

 

 

6,005,946

 

 

 

2,099,314

 

 

 

13,519,615

 

 

 

7,792,445

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from Operations

 

 

(4,686,560)

 

 

(1,729,508)

 

 

(10,416,311)

 

 

(6,931,310)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other (Expense) Income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of Debt Discount

 

 

(610,089)

 

 

(258,306)

 

 

(922,621)

 

 

(524,161)

Loss on Extinguishment of Debt

 

 

-

 

 

 

(263,950)

 

 

(920,797)

 

 

(263,950)

Loss from Derivatives Issued With Debt Greater

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Than Debt Carrying Value

 

 

(867,000)

 

 

-

 

 

 

(1,355,000)

 

 

(561,000)

Gain (Loss) on Fair Market Valuation of

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Derivatives

 

 

771,000

 

 

 

372,400

 

 

 

(595,700)

 

 

1,779,600

 

Interest Expense

 

 

(159,633)

 

 

(108,563)

 

 

(276,193)

 

 

(426,793)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Other (Expense) Income

 

 

(865,722)

 

 

(258,419)

 

 

(4,070,311)

 

 

3,696

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss Before Provision for Income Taxes

 

 

(5,552,282)

 

 

(1,987,927)

 

 

(14,486,622)

 

 

(6,927,614)

Provision for Income Taxes

 

 

410,300

 

 

 

3,000

 

 

 

791,300

 

 

 

8,076

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Loss

 

 

(5,962,582)

 

 

(1,990,927)

 

 

(15,277,922)

 

 

(6,935,690)

Net Loss Attributable to Non-Controlling Interests

 

 

374,823

 

 

 

32,760

 

 

 

629,861

 

 

 

144,433

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET LOSS ATTRIBUTABLE TO TERRA TECH CORP.

 

$(5,587,759)

 

$(1,958,167)

 

$(14,648,061)

 

$(6,791,257)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Loss Per Common Share Attributable to

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Terra Tech Corp. Common Stockholders -

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and Diluted

 

$(0.01)

 

$(0.01)

 

$(0.04)

 

$(0.03)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-Average Number of Common Shares Outstanding - Basic and Diluted

 

 

352,676,081

 

 

 

252,220,146

 

 

 

343,052,572

 

 

 

224,483,147

 

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.


4
Table of Contents

TERRA TECH CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

(UNAUDITED)

 

 

For the Nine Months Ended

 

 

 

September 30,

 

 

 

2016

 

 

2015

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

Net Loss

 

$(14,648,061)

 

$(6,791,257)

Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:

 

 

 

 

 

 

 

 

(Gain) Loss on Fair Market Valuation of Derivatives

 

 

595,700

 

 

 

(1,779,600)

Loss on Extinguishment of Debt

 

 

920,797

 

 

 

263,950

 

Amortization of Debt Discount

 

 

922,621

 

 

 

524,161

 

Depreciation and Amortization

 

 

1,653,791

 

 

 

481,321

 

Warrants Issued With Common Stock and Debt

 

 

-

 

 

 

1,148,069

 

Stock Issued for Compensation

 

 

715,039

 

 

 

680,630

 

Stock Issued for Director Fees

 

 

60,550

 

 

 

-

 

Stock Issued for Services

 

 

20,727

 

 

 

656,186

 

Stock Option Expense

 

 

142,766

 

 

 

-

 

Equity Instruments Issued With Debt Greater Than Debt Carrying Amount

 

 

1,355,000

 

 

 

561,000

 

Change in Accounts Receivable Reserve

 

 

102,253

 

 

 

169,683

 

Changes in Operating Assets and Liabilities:

 

 

 

 

 

 

 

 

Accounts Receivable

 

 

(432,798)

 

 

(440,850)

Prepaid Expenses

 

 

434,824

 

 

 

(1,073)

Inventory

 

 

(1,356,365)

 

 

5,793

 

Deposits

 

 

(3,375)

 

 

(23,072)

Accounts Payable and Accrued Expenses

 

 

3,177,610

 

 

 

1,138,463

 

Income Tax Payable

 

 

1,783,731

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Net Cash Used in Operations

 

 

(4,555,190)

 

 

(3,406,596)

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

 

 

Cash Assumed in Acquisition

 

 

163,566

 

 

 

-

 

Purchase of Property and Equipment

 

 

(3,211,064)

 

 

(590,219)

Purchase of Intangible Assets - Trademarks

 

 

(75,000)

 

 

-

 

 

 

 

 

 

 

 

 

 

Net Cash Used in Investing Activities

 

 

(3,122,498)

 

 

(590,219)

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

Proceeds from Issuance of Notes Payable

 

 

4,928,650

 

 

 

1,650,000

 

Proceeds from Issuance of Common Stock

 

 

3,208,134

 

 

 

3,012,234

 

Proceeds from Exercise of Warrants

 

 

3,150,000

 

 

 

-

 

Payments By Subsidiaries for Non-Controlling Interest

 

 

(629,861)

 

 

(144,433)

 

 

 

 

 

 

 

 

 

Net Cash Provided by Financing Activities

 

 

10,656,923

 

 

 

4,517,801

 

 

 

 

 

 

 

 

 

 

NET CHANGE IN CASH AND CASH EQUIVALENTS

 

 

2,979,235

 

 

 

520,986

 

 

 

 

 

 

 

 

 

 

Cash and Cash Equivalents at Beginning of Period

 

 

418,082

 

 

 

846,650

 

 

 

 

 

 

 

 

 

 

CASH AND CASH EQUIVALENTS AT END OF PERIOD

 

$3,397,317

 

 

$1,367,636

 

 

 

 

 

 

 

 

 

 

SUPPLEMENTAL DISCLOSURE FOR OPERATING ACTIVITIES:

 

 

 

 

 

 

 

 

Cash Paid for Interest

 

$16,500

 

 

$-

 

 

 

 

 

 

 

 

 

 

SUPPLEMENTAL DISCLOSURE FOR FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

Warrant Expense

 

$142,766

 

 

$1,148,069

 

 

 

For the Three Months Ended

 

 

For the Six Months Ended

 

 

 

June 30,

 

 

June 30,

 

 

 

2017

 

 

2016

 

 

2017

 

 

2016

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Revenues

 

$7,842,873

 

 

$9,699,909

 

 

$14,667,329

 

 

$11,248,076

 

Cost of Goods Sold

 

 

6,336,500

 

 

 

8,152,935

 

 

 

12,801,893

 

 

 

9,686,575

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross Profit

 

 

1,506,373

 

 

 

1,546,974

 

 

 

1,865,436

 

 

 

1,561,501

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, General and Administrative Expenses

 

 

6,029,287

 

 

 

5,364,351

 

 

 

12,415,587

 

 

 

7,291,252

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from Operations

 

 

(4,522,914)

 

 

(3,817,377)

 

 

(10,550,151)

 

 

(5,729,751)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Income (Expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of Debt Discount

 

 

(515,654)

 

 

(218,126)

 

 

(1,126,270)

 

 

(312,532)

Loss on Extinguishment of Debt

 

 

(1,639,137)

 

 

 

 

 

(2,678,595)

 

 

(920,797)

Loss from Derivatives Issued with Debt Greater than Debt Carrying Value

 

 

 

 

 

(488,000)

 

 

 

 

 

(488,000)

Gain (Loss) on Fair Market Valuation of Derivatives

 

 

987,200

 

 

 

(206,000)

 

 

2,597,950

 

 

 

(1,366,700)

Interest Expense

 

 

(130,510)

 

 

(60,565)

 

 

(288,343)

 

 

(116,560)

Loss on Fair Market Valuation of Contingent Consideration

 

 

(77,286)

 

 

 

 

 

(4,426,047)

 

 

 

Gain on Settlement of Contingent Consideration

 

 

4,991,571

 

 

 

 

 

 

4,991,571

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Other Income (Expense)

 

 

3,616,184

 

 

 

(972,691)

 

 

(929,734)

 

 

(3,204,589)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss Before Provision for Income Taxes

 

 

(906,730)

 

 

(4,790,068)

 

 

(11,479,885)

 

 

(8,934,340)

Provision for Income Taxes

 

 

 

 

 

381,000

 

 

 

 

 

 

381,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET LOSS

 

 

(906,730)

 

 

(5,171,068)

 

 

(11,479,885)

 

 

(9,315,340)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Loss Attributable to Non-Controlling Interests

 

 

452,961

 

 

 

236,830

 

 

 

914,128

 

 

 

255,038

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET LOSS ATTRIBUTABLE TO TERRA TECH CORP.

 

$(453,769)

 

$(4,934,238)

 

$(10,565,757)

 

$(9,060,302)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Loss Per Common Share Attributable to Terra Tech Corp. Common Stockholders – Basic and Diluted

 

$

 

 

$(0.01)

 

$(0.02)

 

$(0.03)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-Average Number of Common Shares Outstanding – Basic and Diluted

 

 

583,096,376

 

 

 

349,893,516

 

 

 

575,249,192

 

 

 

338,187,946

 

 

The accompanying notes are an integral part of the unaudited consolidated financial statements.


 
5
4
Table of Contents

 

TERRA TECH CORP. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

 

For the Six Months Ended

June 30,

 

 

 

2017

 

 

2016

 

 

 

 

 

 

 

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

Net Loss

 

$(11,479,885)

 

$(9,315,340)

Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:

 

 

 

 

 

 

 

 

(Gain) Loss on Fair Market Valuation of Derivatives

 

 

(2,597,950)

 

 

1,366,700

 

Loss on Fair Market Valuation of Contingent Consideration

 

 

4,426,047

 

 

 

 

Gain on Settlement of Contingent Consideration

 

 

(4,991,571)

 

 

 

Loss on Extinguishment of Debt

 

 

2,678,595

 

 

 

920,797

 

Amortization of Debt Discount

 

 

1,126,270

 

 

 

312,532

 

Deferred Tax Expense

 

 

 

 

 

49,000

 

Depreciation and Amortization

 

 

1,778,782

 

 

 

787,178

 

Warrants Issued with Common Stock and Debt

 

 

211,534

 

 

 

 

Stock Issued for Compensation

 

 

1,356,138

 

 

 

 

Stock Issued for Director Fees

 

 

221,973

 

 

 

60,550

 

Stock Issued for Services

 

 

591,359

 

 

 

20,727

 

Stock Option Expense

 

 

205,019

 

 

 

95,177

 

Equity Instruments Issued with Debt Greater than Debt Carrying Value

 

 

 

 

 

488,000

 

Change in Allowance for Doubtful Accounts

 

 

 

 

 

102,253

 

Changes in Operating Assets and Liabilities:

 

 

 

 

 

 

 

 

Accounts Receivable

 

 

(36,279)

 

 

(369,557)

Inventory

 

 

(1,323,742)

 

 

(472,970)

Prepaid Expenses

 

 

(533,808)

 

 

257,238

 

Other Assets

 

 

(166,925)

 

 

 

Accounts Payable and Accrued Expenses

 

 

1,383,860

 

 

 

2,393,183

 

 

 

 

 

 

 

 

 

 

NET CASH USED IN OPERATING ACTIVITIES

 

 

(7,150,583)

 

 

(3,304,532)

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

 

 

Cash Assumed in Acquisition

 

 

 

 

 

163,566

 

Purchase of Property, Equipment and Leasehold Improvements

 

 

(1,036,233)

 

 

(1,988,587)

Purchase of Intangible Assets – Domain Names

 

 

 

 

 

(75,000)

 

 

 

 

 

 

 

 

 

NET CASH USED IN INVESTING ACTIVITIES

 

 

(1,036,233)

 

 

(1,900,021)

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

Proceeds from Issuance of Notes Payable

 

 

6,000,000

 

 

 

3,250,000

 

Cash Paid for Debt Discount

 

 

(180,000)

 

 

 

Proceeds from Issuance of Common Stock

 

 

3,750,000

 

 

 

3,208,134

 

Payment of Contingent Consideration

 

 

(2,088,000)

 

 

 

Cash Contribution from Non-Controlling Interest

 

 

86,550

 

 

 

 

 

 

 

 

 

 

 

 

 

NET CASH PROVIDED BY FINANCING ACTIVITIES

 

 

7,568,550

 

 

 

6,458,134

 

 

 

 

 

 

 

 

 

 

NET CHANGE IN CASH

 

 

(618,266)

 

 

1,253,581

 

Cash at Beginning of Period

 

 

9,749,572

 

 

 

418,082

 

 

 

 

 

 

 

 

 

 

CASH AT END OF PERIOD

 

$9,131,306

 

 

$1,671,663

 

 

 

 

 

 

 

 

 

 

SUPPLEMENTAL DISCLOSURE FOR OPERATING ACTIVITIES:

 

 

 

 

 

 

 

 

Cash Paid for Interest

 

$

 

 

$10,100

 

 

 

 

 

 

 

 

 

 

NON-CASH INVESTING AND FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

Settlement of Contingent Consideration

 

$4,739,638

 

 

$

 

Gain on Settlement of Contingent Consideration Recorded Against Additional Paid-In Capital

 

$4,692,697

 

 

$

 

Fair Value of Debt Discount Recorded

 

$4,446,000

 

 

$2,824,000

 

Issuance of Common Stock for Debt and Interest Expense

 

$8,564,324

 

 

$

 

The accompanying notes are an integral part of the unaudited consolidated financial statements.

5
Table of Contents

TERRA TECH CORP. AND SUBSIDIARIES

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

THREE AND SIX MONTHS ENDED JUNE 30, 2017 AND 2016

NOTE 1 – DESCRIPTION OF BUSINESS

Organization

References in the Notes to CondensedUnaudited Consolidated Financial Statements (Unaudited)to “the Company”, “Terra Tech”, “we”, “us”, or “our” are intended to mean Terra Tech Corp., individually, or as the context requires, collectively with its subsidiaries on a consolidated basis.

Three

Through MediFarm, LLC, a Nevada limited liability company (“MediFarm”), MediFarm I, LLC, a Nevada limited liability company (“MediFarm I”), and Nine Months Ended September 30,MediFarm II, LLC, a Nevada limited liability company (“MediFarm II”), subsidiaries in which the Company owns interests, the Company operates and/or plans to operate medical marijuana dispensary facilities, cultivation, and production facilities in Nevada. Through IVXX, LLC, a Nevada limited liability company (“IVXX LLC”), and IVXX, Inc., a California corporation (“IVXX Inc.”; together with IVXX LLC, “IVXX”), the Company’s wholly-owned subsidiary, the Company produces and sells a line of cannabis flowers, as well as a line of cannabis pure concentrates. Most recently, the Company formed another subsidiary, MediFarm I Real Estate, LLC, a Nevada limited liability company (“MediFarm I RE”), which owns the real property on which a medical marijuana dispensary will be constructed. The dispensary will be operated by MediFarm I. Through Black Oak Gallery, a California corporation (“Black Oak”), we operate a medical marijuana retail dispensary, a medical marijuana cultivation facility, and have a second medical marijuana cultivation facility in the early stages of construction, all in Oakland, California. The Company is a wholesale seller of locally grown hydroponic produce, herbs and floral products through its wholly-owned subsidiary, Edible Garden Corp., a Nevada corporation (“Edible Garden”).

On April 1, 2016, the Company acquired Black Oak. Black Oak operates a medical marijuana retail dispensary in Oakland, California under the name Blüm, pursuant to that certain Agreement and Plan of Merger, dated December 23, 2015 (the “Merger Agreement”), with Generic Merger Sub, Inc., a California corporation and our wholly-owned subsidiary, and Black Oak.

Since the Merger was completed on April 1, 2016, Black Oak’s financial results are included in our unaudited consolidated financial statements subsequent to that date.

 

NOTE 12 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization

References in this document to the “Company,” “Terra Tech,” “we,” “us,” or “our” are intended to mean Terra Tech Corp. (“Terra Tech”), individually, or as the context requires, collectively with its subsidiaries on a consolidated basis.

We were incorporated in Nevada on July 22, 2008, under the name Private Secretary, Inc. Our original business was developing a software program that would allow for automatic call processing through voice-over-Internet protocol, or “VoIP”, technology. Our operations were limited to capital formation, organization, and development of its business plan and target customer market. We generated no revenue. We changed our name to Terra Tech Corp. on January 27, 2012.

On February 9, 2012, we completed a reverse-triangular merger with GrowOp Technology Ltd., a Nevada corporation (“GrowOp Technology”), whereby we acquired all of the issued and outstanding shares of GrowOp Technology and in exchange we issued: (i) 33,998,520 shares of its common stock, (ii) 100 shares of Series A Preferred Stock, convertible into shares of common stock on a one-for-one basis, and (iii) 14,750,000 shares of Series B Preferred Stock, with each share convertible into 5.384325537 shares of common stock. As a result of the merger, GrowOp Technology became our wholly-owned subsidiary. Following the merger, Terra Tech ceased its prior operations and is now solely a holding company. Through GrowOp Technology, we engage in the design, marketing, and sale of hydroponic equipment with proprietary technology to create sustainable solutions for the cultivation of indoor agriculture.

We are also a wholesale seller of locally grown hydroponic produce, herbs, and florals through our wholly-owned subsidiary, Edible Garden Corporation, a Nevada corporation (“Edible Garden”). We acquired all of the issued and outstanding shares in Edible Garden pursuant to a Share Exchange Agreement, dated March 23, 2013 (the “Share Exchange Agreement”), entered into by and among Terra Tech, Edible Garden, and the stockholders of Edible Garden. Pursuant to the Share Exchange Agreement, we offered and sold 1,250,000 shares of our common stock in consideration for all the issued and outstanding shares in Edible Garden. Separately, Amy Almsteier, one of our stockholders and a director (and, at that time, an executive officer), offered and sold 7,650,000 shares of Series B Preferred Stock to Kenneth Vande Vrede, Michael Vande Vrede, Steven Vande Vrede, Daniel Vande Vrede, Beverly Willekes, and David Vande Vrede (collectively, the “Former EG Principal Stockholders”).

On March 19, 2014, we formed MediFarm, LLC, a Nevada limited liability company (“MediFarm”), as a subsidiary. On July 18, 2014, we formed MediFarm I, LLC, a Nevada limited liability company (“MediFarm I”), as a subsidiary. On July 30, 2014, we formed MediFarm II, LLC, a Nevada limited liability company (“MediFarm II”), as a subsidiary. Through MediFarm, MediFarm I, and MediFarm II, we are currently operating one medical marijuana dispensary facility in Nevada and plan to operate additional medical marijuana cultivation, production, and dispensary facilities in that state. In April 2016, MediFarm commenced operations at its dispensary in Las Vegas, Nevada under the “Blüm” brand.

On September 16, 2014, we formed IVXX, LLC, a Nevada limited liability company (“IVXX”), as a wholly-owned subsidiary, for the purpose of producing a line of cannabis flowers and cigarettes, as well as a complete line of cannabis pure concentrates including: oils, waxes, shatters, and clears. We began producing and selling IVXX’s products during the first quarter of fiscal 2015. We currently offer these products to 200 select dispensaries in California. We use our extraction lab located in Oakland, California to manufacture these products. IVXX also sells clothing, apparel, and other various branded products.


6
Table of Contents

TERRA TECH CORP. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

Three and Nine Months Ended September 30, 2016 and 2015

NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

On October 14, 2015, we formed MediFarm I Real Estate, LLC, a Nevada limited liability company (“MediFarm I RE”). MediFarm I RE is a real estate holding company that owns the real property and building at which a medical marijuana dispensary facility will be located. It is our intention that MediFarm I will operate the medical marijuana dispensary. We own 50% of the membership interests in MediFarm I RE. The remaining membership interests are owned by Forever Young Investments, LLC (50%), an otherwise unaffiliated entity.

On April 1, 2016, we acquired Black Oak Gallery, a California corporation (“Black Oak”). Black Oak operates a medical marijuana dispensary in Oakland, California under the name Blüm, pursuant to that certain Agreement and Plan of Merger, dated December 23, 2015 (the “Merger Agreement”), with Generic Merger Sub, Inc., a California corporation and our wholly-owned subsidiary (the “Merger Sub”), and Black Oak. The Merger Agreement was amended by a First Amendment to the Agreement and Plan of Merger, dated February 29, 2016. Pursuant to the Merger Agreement, the Merger Sub merged with and into Black Oak, with Black Oak as the surviving corporation, and became our wholly-owned subsidiary (the “Merger”). The Merger is intended to qualify for Federal income tax purposes as a tax-free reorganization under the provisions of Section 368(a) of the Internal Revenue Code of 1986, as amended.

Subject to the terms and conditions of the Merger Agreement, at the closing of the Merger, the outstanding shares of common stock of Black Oak held by (i) three of the current shareholders of Black Oak (the “Group A Shareholders”) were converted into the right to receive approximately 8,166 shares of our Series Z preferred stock, par value $0.001 per share (“Series Z Preferred Stock”), of which approximately 1,175 shares of Series Z Preferred Stock were issued and paid at closing, and approximately 8,668,700 shares of our Series B preferred stock, par value $0.001 per share (“Series B Preferred Stock”), of which approximately 1,248,300 shares of Series B Preferred Stock were issued and paid at closing and (ii) the remaining shareholders of Black Oak (the “Group B Shareholders”) were converted into the right to receive approximately 21,378 shares of our Series Q preferred stock, par value $0.001 per share (“Series Q Preferred Stock), of which approximately 3,695 shares of Series Q Preferred Stock were issued and paid at closing. The shares of Series Z Preferred Stock, Series B Preferred Stock, and Series Q Preferred Stock that were issued but not paid to the Black Oak shareholders at closing are subject to certain holdback and lock-up provisions, and held in an escrow account as security for the satisfaction of any post-closing adjustments or indemnification claims, as provided for in the Merger Agreement. Each share of Series Q Preferred Stock was converted into 5,000 shares of our common stock and each share of Series Z Preferred Stock was converted into 1,857 shares of our Series B Preferred Stock, in each case immediately upon our filing with the Secretary of State of the State of Nevada an Amendment to our Articles of Incorporation to increase our authorized capital for, among other reasons, satisfaction of the terms of this potential transaction. Accordingly, the approximately 21,378 shares of Series Q Preferred Stock was issued to the Group B Shareholders was converted into approximately 106,890,000 shares of common stock and the approximately 8,166 shares of Series Z Preferred Stock was issued to the Group A Shareholders was converted into approximately 15,164,262 shares of Series B Preferred Stock. The Series Z Preferred Stock was intended to mirror the rights of the holders of our Series B Preferred Stock. Each share of our Series B Preferred Stock remains convertible into 5.384325537 shares of our common stock. The aggregate fair market value of the securities issued in the Merger was approximately $22.9 million. The Group B Shareholders may also receive cash consideration equal to approximately $2.1 million.

The securities paid to the Group A Shareholders and the Group B Shareholders are subject to certain post-closing adjustments that are based on certain performance indicators as of the first anniversary of the closing date of the Merger. The first indicator is based on the performance of the volume-weighted average price of our common stock on the first anniversary of the closing date of the Merger compared to the price of our common stock on the date of the Merger Agreement. The second indicator is based on our revenues for the twelve-month period following the closing date of the Merger. A portion of the securities that the Group A Shareholders and the Group B Shareholders are entitled to receive at closing of the Merger will be held in an escrow until the first anniversary of the closing date of the Merger and the post-closing adjustments are complete.


7
Table of Contents

TERRA TECH CORP. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

Three and Nine Months Ended September 30, 2016 and 2015

NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Since the Merger was completed on April 1, 2016, Black Oak’s financial results are included in our unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2016.

 

Basis of Presentation

 

The accompanying unaudited consolidated financial statements include all of the accounts of Terra Tech. and subsidiaries. These unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted accounting principles in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAPgenerally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments consisting(consisting only of normal recurring adjustments and accrualsadjustments) considered necessary for a fair presentation have been included. Operating results for the three and ninesix months ended SeptemberJune 30, 20162017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016.2017.

 

Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP haveThe consolidated balance sheet at December 31, 2016 has been omitted in accordance with the rules and regulations of the SEC. These unaudited condensed consolidated financial statements should be read in conjunction withderived from the audited consolidated financial statements at that date but does not include all of the information and accompanying notesfootnotes required by generally accepted accounting principles for complete financial statements. For further information, refer to the consolidated financial statements and footnotes thereto included in Item 8 of Part II, “Financial Statements and Supplementary Data,” of our 2015 Annual ReportTerra Tech’s annual report on Form 10-K.10-K for the year ended December 31, 2016.

6
Table of Contents

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES(Continued)

Non-Controlling Interest

Non-controlling interest is shown as a component of shareholders’ equity on the consolidated balance sheets and the share of income (loss) attributable to non-controlling interest is shown as a component of income (loss) in the consolidated statements of operations.

 

Use of Estimates

 

The preparation of the financial statements in conformity with U.S. GAAPUnited States generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Cash and Cash EquivalentsReclassifications

 

CashCertain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications did not affect net loss and all highly liquid investments with a maturity of three months or less from the date of purchase, including money market mutual funds, short-term time deposits, and government agency and corporate obligations, are classified as cash and cash equivalents.shareholders’ equity.

 

Accounts ReceivableInventory

 

We value our inventory at the lower of the actual cost of our inventory, as determined using the first-in, first-out method, or its current estimated net realizable value (“NRV”). ASU No. 2015-11, “Inventory (Topic 330): Simplifying the Measurement of Inventory”, defines NRV as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. We periodically review all outstanding accounts receivableour physical inventory for collectabilityexcess, obsolete, and potentially impaired items and reserve accordingly. Our reserve estimate for excess and obsolete is based on a quarterly basis. An allowanceexpected future use. Our reserve estimates have historically been consistent with our actual experience as evidenced by actual sale or disposal of the goods.

Prepaid Expenses

Prepaid expenses consist of various payments that the Company has made in advance for doubtful accounts is recorded for any amounts deemed uncollectable. We do not accrue interest receivable on past due accounts receivable. There was an allowance for doubtful accounts of $159,169 at September 30, 2016goods or services to be received in the future. These prepaid expenses include advertising, insurance and $184,642 at December 31, 2015.service contracts requiring up-front payments.

 

Property, Equipment and Leasehold Improvements

 

Property, equipment and leasehold improvements are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets: 3 toassets. The approximate useful lives for depreciation of our property, equipment and leasehold improvements are as follows: 32 years for machinerybuildings; three to eight years for furniture and equipment, leasehold improvements,equipment; and buildings are amortized overthe shorter of the estimated useful life.life or the underlying lease term for leasehold improvements. Repairs and maintenance expenditures that do not extend the useful lives of related assets are expensed as incurred.

Goodwill

Goodwill is measured as the excess of consideration transferred and the net of the acquisition date fair value of assets acquired and liabilities assumed in a business acquisition. Goodwill is not amortized for accounting purposes.

7
Table of Contents

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES(Continued)

We test property and equipmentreview the goodwill allocated to each of our reporting units for possible impairment annually for recoverability oras of August 1 and whenever events or changes in circumstances indicate that the carryits carrying amount may not be recoverable. For the year ended December 31, 2015 andWhen assessing goodwill for the nine months ended September 30, 2016,impairment, we have concludedthe option to first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the sumfair value of a reporting unit is less than its carrying amount. If, after assessing the totality of events or circumstances, we determine it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then we perform a two-step impairment test. If we conclude otherwise, then no further action is taken. We also have the option to bypass the qualitative assessment and only perform a quantitative assessment, which is the first step of the undiscounted cash flows exceedstwo-step impairment test. In the carrytwo-step impairment test, we measure the recoverability of goodwill by comparing a reporting unit’s carrying amount, including goodwill, to the estimated fair value of the assets.


8
Table of Contents

TERRA TECH CORP. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

Three and Nine Months Ended September 30, 2016 and 2015

NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)reporting unit.

 

Intangibles

 

Intangible assets are stated at historical cost and amortized over their estimated useful lives. We use a straight-line method of amortization, unless a method that better reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up can be reliably determined. The approximate useful lives for amortization of our intangible assets are as follows: customer relationships, five to 15 years; trade names, five to 15 years; and dispensary license, 15 years.

Customer Relationships

5 to 12 Years

Trade Names

2 to 8 Years

Dispensary License

14 Years

Patent

2 Years

 

We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. ConditionsIntangible assets that mayhave indefinite useful lives are tested annually for impairment, and are tested for impairment more frequently if events and circumstances indicate that the asset might be impaired. An impairment include, but are not limitedloss is recognized to a significant adverse change in legal factors or business climatethe extent that could affect the value of an asset, a product recall, or an adverse action or assessment by a regulator. If an impairment indicator exists, we test the intangible asset for recoverability. For purposescarrying amount of the recoverability test, we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset (asset group)reporting unit exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset (asset group), we will write the carrying value down to theits fair value in the period identified.value.

 

We calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset using a risk-adjusted discount rate. In determining our estimated future cash flows associated with our intangible assets, we use estimates and assumptions about future revenue contributions, cost structures and remaining useful lives of the asset (asset group).

The Carrying Value, Recoverability and Impairment of Long-Lived Assets

 

We have adopted paragraph 360-10-35-17 of FASB Accounting Standards Codification (“ASC”) for our long-lived assets. Our long -livedlong-lived assets are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. We assess the recoverability of our long-lived assets by comparing the projected undiscounted net cash flows associated with the related long-lived asset or group of assets over their remaining estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets. Fair value is generally determined using the assets expected future discounted cash flows or market value, if readily determinable. If long-lived assets are determined to be recoverable, but the newly determined remaining estimated useful lives are shorter than originally estimated, the net book values of the long-lived assets are depreciated over the newly determined remaining estimated useful lives.

 

We considerOther Assets

Other assets are comprised primarily of security deposits for leased properties in California, Nevada and New Jersey. The deposits will be returned at the following to be some examples of important indicators that may trigger an impairment review: (i) significant under-performance or losses of assets relative to expected historical or projected future operating results; (ii) significant changes in the manner or use of assets or in our overall strategy with respect to the manner of useend of the acquired assets or changes in our overall business strategy; (iii) significant negative industry or economic trends; (iv) increased competitive pressures; (v) a significant decline in our stock price for a sustained period of time; and (vi) regulatory changes. We evaluate acquired assets for potential impairment indicators at least annually and more frequently upon the occurrence of such events. The impairment charges, if any, are included in operating expenses in the accompanying statements of operations. Based on the test results, no impairments have occurred.lease term.


 
9
8
Table of Contents

TERRA TECH CORP. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

Three and Nine Months Ended September 30, 2016 and 2015

 

NOTE 12 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES(Continued)

Deposits

Deposits are for stores, land and utility companies located in California, Nevada and New Jersey.

 

Revenue Recognition

Cannabis Products

We recognize revenue from product sales net of discounts, rebates, promotional adjustments, price adjustments, and estimated returns and upon transfer of title and risk to the customer, which occurs at shipping (F.O.B. terms). Upon shipment, we have no further performance obligations, selling price is fixed, and collection is reasonably assured.

 

We recognize revenue in accordance with ASC 605, Revenue RecognitionRecognition”,,” by recognizing as revenue the fees we charge customers because persuasive evidence of an arrangement exists, the fees we charge are substantially fixed or determinable during the period that we provide the goods or services, we and our customers understand the specific nature and terms of the agreed upon transactions, and payment is made for the goods or services when they have been rendered.

 

Cannabis Dispensary, Cultivation and Production

We recognize revenue from manufacturing and distribution product sales and upon transfer of title and risk to the customer, which occurs either at shipping (F.O.B. terms), or upon sell through, depending on the arrangement.

Revenue from our retail dispensaries is recognized net of discounts, rebates, promotional adjustments, price adjustments and returns, and net of taxes collected from customers that are remitted to governmental authorities, with the collected taxes recorded as current liabilities until remitted to the relevant government authority. Revenue is recorded upon transfer of title and risk to the customer, which occurs at the time customers take delivery of our products at our retail dispensary.dispensaries. Upon purchase, we have no further performance obligations and collection is assured as sales are paid for at time of purchase.

 

Revenue related to the sale of consignment inventory is not recognized until the product is pulled from inventory and sold directly to our end-customers at our retail dispensary.end-customers. We recognize revenue from the sale of consignment inventory on a gross basis, as it haswe have determined that it isthat: 1) we are the primary obligor to the customer, hascustomer; 2) we have latitude in establishing the sales prices and profit margins of its products, hasour products; 3) we have discretion in selecting its suppliers, isour suppliers; 4) we are responsible for loss or damage to consigned inventoryinventory; and through its5) our customer validation process performs an important part of the process of providing such products to authorized customers. We believe that these factors outweigh the fact that we do not have title to the consigned inventory prior to its sale.

 

During the threeHerbs and nine months ended September 30, 2016, sales returns were not significant and, as such, no sales return allowance has been recorded as of September 30, 2016.

Hydroponic Produce Products

 

We recognize revenue from products grown in our greenhouses and sold net of discounts, rebates, promotional adjustments, price adjustments, and estimated returns and upon transfer of title and risk to the customer, which occurs at shipping (F.O.B. terms). Upon shipment, we have no further performance obligations, selling price is fixed, and collection is reasonably assured.


10
Table of Contents

TERRA TECH CORP. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

Three and Nine Months Ended September 30, 2016 and 2015

NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

For sales for which we use an outside grower, we evaluate whether it is appropriate to record the gross amount of product sales and related costs or the net amount earned as commissions. We determine the product specifications, cultivation, and packaging, while disclosing trade and operational secrets, greenhouse technologies, and nutrients used to grow. We are the primary obligor in the transaction because it is our brand that is sold into the retail channel. We are subject to inventory risk until product is accepted by the retailer. We bear credit risk for the amount billed to the retailer and, thus, must pay the grower in the event the selling price is not collected. This revenue is recorded at the gross sale price once the retailer has accepted delivery, selling price is fixed, and collection is reasonably assured.

 

Cost of Goods Sold

 

Cannabis ProductsDispensary, Cultivation and Production

 

Cost of goods sold includes the costs directly attributable to product sales and includes amounts paid for finished goods, such as flower, edibles, and concentrates, as well as packaging and other supplies, fees for services and processing, other expenses for services, and allocated overhead. Overhead expenses include allocations of rent, administrative salaries, utilities, and related costs. It also includes the cost incurred in producing the oils, waxes, shatters, and clears sold by IVXX.

 

HydroponicHerbs and Produce Products

 

Cost of goods sold are for the plants grown, packaging, other supplies and purchased andplants that are sold into the retail marketplace by Edible Garden. Other expenses include freight, allocations of rent, repairs and maintenance, and utilities.

9
Table of Contents

 

Loyalty Rewards ProgramNOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES(Continued)

 

We offerStock-Based Compensation

The Company accounts for its stock-based awards in accordance with ASC Subtopic 718-10, “Compensation”, which requires fair value measurement on the grant date and recognition of compensation expense for all share-based payment awards made to employees and directors, including restricted stock awards. For stock options, the Company estimates the fair value using a customer loyalty rewards program that allows members to earn discountsclosed option valuation (Black-Scholes) model. The fair value of restricted stock awards is based upon the quoted market price of the common shares on future purchases.the date of grant. The amountfair value is then expensed over the requisite service periods of unused discounts earned by our loyalty rewards program membersthe awards, net of estimated forfeitures, which is included in accrued liabilitiesgenerally the performance period and recorded as a reduction of revenue at the time a qualifying purchase is made. Revenuerelated amount is recognized when pointsin the consolidated statements of operations.

Warrants

ASC 815-40, “Contracts in Entity’s Own Equity”, requires freestanding contracts that are redeemedsettled in a company’s own stock, including common stock warrants, to be designated as an equity instrument, asset or a liability. Under the provisions of ASC 815-40, a contract designated as an asset or a liability must be carried at fair value on a company’s balance sheet, with any changes in fair value recorded in the company’s results of operations. A contract designated as an equity instrument must be included within equity, and no fair value adjustments are required from period to period.

ASC 815, “Derivatives and Hedging”, requires all derivatives to be recorded on the balance sheet at fair value. Furthermore, ASC 815 precludes contracts issued or held by the loyalty rewards program member. We began offering customers the loyalty rewards program during April 2015a reporting entity that are both (1) indexed to its own stock and the value(2) classified as stockholders’ equity in its statement of points accruedfinancial position from being treated as of September 30, 2016 was $25,097.derivative instruments.

 

Research and Development

 

Research and development costs are expensed as incurred.

 

Income Taxes

 

We provide for income taxes based on enacted tax law and statutory tax rates at which items of income and expensesexpense are expected to be settled in our income tax return. Certain items of revenue and expense are reported for Federal income tax purposes in different periods than for financial reporting purposes, thereby resulting in deferred income taxes. Deferred taxes are also recognized for operating losses that are available to offset future taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. The Company hasWe have incurred net operating losses for financial-reporting and tax-reporting purposes. Accordingly, for FederalAt June 30, 2017 and state income tax purposes, the benefit for income taxes has beenDecember 31, 2016, such net operating losses were offset entirely by a valuation allowance against the related Federal and state deferred tax asset for the nine months ended September 30, 2016.


11
Table of Contents
allowance.

 

TERRA TECH CORP. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

ThreeThe Company recognizes uncertain tax positions based on a benefit recognition model. Provided that the tax position is deemed more likely than not of being sustained, the Company recognizes the largest amount of tax benefit that is greater than 50% likely of being ultimately realized upon settlement. The tax position is derecognized when it is no longer more likely than not of being sustained. The Company classifies income tax related interest and Nine Months Ended September 30, 2016penalties as interest expense and 2015

NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)selling, general and administrative expense, respectively, on the consolidated statements of operations.

 

Loss Per Common Share

 

Net loss per share is computed inIn accordance with the provisions of ASC 260, “Earnings Per Share,”Share”, net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. During a loss period, the effect of the potential exercise of stock options, warrants, convertible preferred stock, and convertible debt are not considered in the diluted income (loss)loss per share calculation since the effect would be anti-dilutive. The results of operations were a net loss for the ninethree and six months ended SeptemberJune 30, 2016; therefore,2017 and 2016. Therefore, the basic and diluted weighted-average shares of common stock outstanding were the same.same for both periods.

10
Table of Contents

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES(Continued)

 

Fair Value of Financial Instruments

 

We apply fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. We define fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities whichthat are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:

 

Level 1 - Quoted prices in active markets for identical assets or liabilities.

 

Level 2 - Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

Level 3 - Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.

Our valuation techniques used to measure the fair value of money market funds and certain marketable equity securities were derived from quoted prices in active markets for identical assets or liabilities. The valuation techniques used to measure the fair value of all other financial instruments, all of which have counterparties with high credit ratings, were valued based on quoted market prices or model driven valuations using significant inputs derived from or corroborated by observable market data.

 

In accordance with the fair value accounting requirements, companies may choose to measure eligible financial instruments and certain other items at fair value. We have not elected the fair value option for any eligible financial instruments.


12
Table of Contents

TERRA TECH CORP. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

Three and Nine Months Ended September 30, 2016 and 2015

NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Recently Issued Accounting Standards

 

LeasesFASB ASU 2017-04 (Topic 350), “Intangibles - Goodwill and Others” – Issued in January 2017, ASU 2017-04 simplifies how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit’s goodwill with the carrying amount of that goodwill. ASU 2017-04 is effective for annual periods beginning after December 15, 2019 including interim periods within those periods. We are currently evaluating the effect that ASU 2017-04 will have on our consolidated financial statements and related disclosures.

 

InFASB ASU 2017-01 (Topic 805), “Business Combinations: Clarifying the Definition of a Business” – Issued in January 2017, ASU 2017-01 revises the definition of a business and provides new guidance in evaluating when a set of transferred assets and activities is a business. This guidance will be effective for the Company in the first fiscal quarter of 2018 on a prospective basis, and early adoption is permitted. The Company does not expect the standard to have a material impact on our consolidated financial statements.

FASB ASU 2016-15, “Classification of Certain Cash Receipts and Cash Payments (a consensus of the Emerging Issues Task Force)” – Issued in August 2016, the amendments in ASU 2016-15 address eight specific cash flow issues and apply to all entities that are required to present a statement of cash flows under ASC Topic 230, “Statement of Cash Flows”. The amendments in ASU 2016-15 are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including adoption during an interim period. The Company has not yet completed the analysis of how adopting this guidance will affect its consolidated financial statements.

11
Table of Contents

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES(Continued)

FASB ASU No. 2016-02 (Topic 842), “Leases” – Issued in February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)ASU No. 2016-02 Leases (Topic 842) (“ASU 2016-02”). ASU 2016-02 requireswill require entities to recognize right-of-use assets and lease liabilities on the balance sheet for the rights and obligations created by all leases, including operating leases, with terms of more than 12 months. The new standard also requires additional disclosures on the amount, timing, and uncertainty of cash flows arising from leases. These disclosures include qualitative and quantitative information. The new standard will be effective for the Company on January 1, 2019. Early adoption is permitted. The Company is in the process of evaluating the impact the adoption of this standard will have on its consolidated financial statements and related disclosures.

 

Balance Sheet ClassificationFASB ASU No. 2014-09 (Topic 606), “Revenue from Contracts with Customers” – Issued in May 2014, ASU 2014-09 will require an entity to recognize revenue when it transfers promised goods or services to customers using a five-step model that requires entities to exercise judgment when considering the terms of Deferred Taxes

the contracts. In NovemberAugust 2015, the FASB issued ASU No. 2015-17, Income Taxes2015-14, “Revenue from Contracts with Customers (Topic 740)606): Balance Sheet ClassificationDeferral of Deferred Taxes (“the Effective Date”. This amendment defers the effective date of ASU 2015-17”).2014-09 by one year. In March 2016, the FASB issued ASU 2015-17 requires entities2016- 08, “Principal versus Agent Considerations (Reporting Gross versus Net)”, which amends the principal versus agent guidance and clarifies that the analysis must focus on whether the entity has control of the goods or services before they are transferred to present deferred tax assetsthe customer. In addition, the FASB issued ASU Nos. 2016-20, “Technical Corrections and deferred tax liabilities as noncurrentImprovements to Topic 606, Revenue from Contracts with Customers” and 2016-12, “Narrow-Scope Improvements and Practical Expedients”, both of which provide additional clarification of certain provisions in a classified balance sheet. The new standard isTopic 606. These ASC updates are effective for public entities for annual reporting periods beginning after December 15, 2016, with2017, but early adoption allowed on either a prospective or retrospective basis. The Company adopted ASU 2015-17, on a prospective basis, for itsis permitted. Early adoption is permitted only as of annual period ending December 31, 2015. Accordingly, the accompanying unaudited consolidated balance sheet at September 30, 2016 reflects the presentation of deferred tax assets and deferred tax liabilities in accordance with ASU 2015-17.

Inventory Measurement

In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory (“ASU 2015-11”), which requires entities to measure inventory at the lower of cost and net realizable value (“NRV”). A SU 2015-11 defines NRV as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The ASU will not apply to inventories that are measured by using either the last-in, first-out method or the retail inventory method. The guidance in ASU 2015-11 is effective prospectively for fiscal years beginningreporting periods after December 15, 2016, and interim periods therein. Early adoption is permitted. Upon2016. The standard permits the use of either the retrospective or cumulative effect transition entities must disclose the nature of and reason for the accounting change. The Company does not expect that the adoption of this standard will have a material effect on its consolidated financial statements.

Going Concern Disclosures

In August 2014, the FASB issued ASU No. 2014-15: Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). ASU 2014-15 requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statementsmethod. We are issued and provides guidance on determining when and how to disclose going concern uncertaintiescurrently in the financial statements. Certain disclosures will be required if conditions give riseprocess of evaluating all revenue streams, accounting policies, practices and reporting to substantial doubt about an entity’s ability to continue as a going concern. ASU 2014-15 is effective for annualidentify and interim reporting periods ending after December 15, 2016, with early adoption permitted. We do not expect that the adoption of this standard will have a material effectunderstand any impact on our consolidated financial statements.


13
Table of Contents

TERRA TECH CORP. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

Three and Nine Months Ended September 30, 2016 and 2015

NOTE 2 – GOING CONCERN

Our future success is dependent upon our ability to achieve profitable operations and generate cash from operating activities, and upon additional financing. Management believes they can raise the appropriate funds needed to support their business plan and develop an operating company that is cash-flow positive.

However, we incurred net losses for the nine months ended September 30, 2016, and have an accumulated deficit of $60,600,170 at September 30, 2016. We have not been able to generate sufficient cash from operating activities to fund its ongoing operations. There is no guarantee that we will be able to generate enough revenue and/or raise capital to support our operations. These factors raise substantial doubt about our ability to continue as a going concern.

The unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability or classification of recorded assets and liabilities that might result should we be unable to continue as a going concern.

 

NOTE 3 – CONCENTRATIONS OF BUSINESS AND CREDIT RISK

 

We maintainThe Company maintains cash balances in several financial institutions that are insured by the Federal Deposit Insurance Corporation up to certain federal limitations. At times, the Company’s cash balance exceeds these federal limitations.

 

We provideThe Company provides credit in the normal course of business to customers located throughout the U.S. We performThe Company performs ongoing credit evaluations of ourits customers and maintainmaintains allowances for doubtful accounts based on factors surrounding the credit risk of specific customers, historical trends, and other information.

 

NOTE 4 – ACQUISITIONS

In March 2016, we acquired certain assets from Therapeutics Medical. The fair value of total consideration transferred in connection with the acquisition was $1,250,000. Of the total purchase price, $58,622 was attributed to finished goods inventory, $191,378 was attributed to the existing brands, and $1,000,000 was attributed to the trademarks, patent, customer list, and vendor numbers. We have determined that the trademarks, patent, customer list, and vendor numbers have a useful life of 5 years.

On April 1, 2016, we acquired all of the assets of Black Oak. The acquisition of Black Oak was accounted for in accordance with ASC 805-10 Business Combinations. The assets consisted primarily of the intellectual property and established marketing associated with the brand name “Blüm,” including its website, www.blumoak.com, the medical marijuana dispensary license, and customer relationships.


14
Table of Contents

TERRA TECH CORP. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

Three and Nine Months Ended September 30, 2016 and 2015

NOTE 4 – ACQUISITIONS (Continued)INVENTORY

 

The following table summarizes the acquisition with a purchase priceRaw materials consist of $51,489,665:

Current assets, (inclusive of cash of $163,566)

 

$792,447

 

Property, plant and equipment

 

 

681,896

 

Customer relationships

 

 

7,480,800

 

Trade Name

 

 

4,280,000

 

Dispensary license

 

 

8,214,700

 

Liabilities

 

 

(2,355,938)

Total identifiable net assets

 

19,093,905

 

Goodwill

 

 

32,395,760

 

Net assets

 

$51,489,665

 

The estimated purchase price of Black Oak (for accounting purposes) was $51,489,665. The purchase price was determined based on the value of the shares of our common stock issuable upon conversion of the various series of preferred stock issued in connection with the acquisition, or $0.2620 per share of common stock, which was the closing sales price of our common stock on April 1, 2016, as quoted on the OTC Market Group Inc.’s OTCQX tier.

The purchase price represents the sum of:

(i) the issuance of approximately 1,176 shares of our Series Z Preferred Stock (or, upon conversion, 11,759,242 shares of our common stock), approximately 1,248,300 shares of our Series B Preferred Stock (or, upon conversion, 6,721,254 shares of our common stock), and approximately 3,696 shares of our Series Q Preferred Stock (or, upon conversion, 18,480,493 shares of our common stock), which collectively, were converted into 36,960,989 shares of our common stock (the “Closing Consideration”); and

(ii) the issuance of approximately 4,210 shares of our Series Z Preferred Stock (or, upon conversion, 42,098,295 shares of our common stock), approximately 4,468,872 shares of our Series B Preferred Stock (or, upon conversion, 24,061,862 shares of our common stock), and approximately 8,945 shares of our Series Q Preferred Stock (or, upon conversion, 44,722,796 shares of our common stock), which collectively, were converted into approximately 110,882,953 shares of our common stock (the “Lockup Consideration”); and

(iii) the issuance of approximately 2,781 shares of our Series Z Preferred Stock (or, upon conversion, 27,804,112 shares of our common stock), approximately 2,951,528 shares of our Series B Preferred Stock (or, upon conversion, 15,891,988 shares of our common stock), and approximately 8,739 shares of our Series Q Preferred Stock (or, upon conversion, 43,696,102 shares of our common stock), which collectively, were converted into approximately 87,392,202 shares of our common stock (the “Holdback Consideration”); and

(iv) the contingent cash consideration of up to $2,088,000 pursuant to certain earn-out provisions set forth in the Merger Agreement, payable to the Group B Shareholders (the “Performance-based Cash Consideration”).


15
Table of Contents

TERRA TECH CORP. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

Three and Nine Months Ended September 30, 2016 and 2015

NOTE 4 – ACQUISITIONS (Continued)

Closing Consideration

Pursuant to the Merger Agreement, the Closing Consideration was issued and paid on April 1, 2016, the closing date.

Lockup Consideration

Pursuant to the Merger Agreement, the Lockup Consideration was issued on April 1, 2016, the closing date; however, such shares will be held in an escrow account for a period of one year.

Holdback Consideration

Pursuant to the Merger Agreement, Holdback Consideration was issued on April 1, 2016, the closing date; however, such shares will be held in an escrow account for a period of one year as security for the satisfaction of any post-closing adjustments or indemnification claims as provided for in the Merger Agreement.

Performance-Based Cash Consideration

Pursuant to the Merger Agreement, the Performance-Based Cash Consideration is to be paid in cash on approximately the one-year anniversary date of the Merger Agreement and is subject to certain holdback provisions. Accordingly, the Performance-Based Cash Consideration is unpaid and recorded as contingent consideration as security for the satisfaction of any post-closing adjustments or indemnification claims as provided for in the Merger Agreement.

The below chart outlines a summary of the purchase price:

Purchase Price Detail

 

Series B

Preferred Stock

 

 

Series Q

Preferred Stock

 

 

Series Z

Preferred Stock

 

 

Preferred Stock Converted Into Common Stock

 

 

Total

Consideration

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Closing Consideration

 

 

1,248,300

 

 

 

3,696

 

 

 

1,176

 

 

 

36,960,989

 

 

$9,683,779

 

Lockup Consideration

 

 

4,468,872

 

 

 

8,945

 

 

 

4,210

 

 

 

110,882,953

 

 

 

29,051,334

 

Holdback Consideration

 

 

2,951,528

 

 

 

8,739

 

 

 

2,781

 

 

 

87,392,202

 

 

 

11,324,969

 

Performance-based Cash Consideration

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

1,429,583

 

Totals

 

 

8,668,700

 

 

 

21,380

 

 

 

8,167

 

 

 

235,236,144

 

 

$51,489,665

 

The Series Q Preferred Stock was converted into 106,890,000 shares of common stock in September 2016. The Series Z Preferred Stock was converted into 15,164,262 Series B Preferred Stock in September 2016.


16
Table of Contents

TERRA TECH CORP. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

Three and Nine Months Ended September 30, 2016 and 2015

NOTE 5 – INVENTORY

Inventory consists of raw materials for Edible Garden’s herb produce, and floral product lines and material for IVXX’s line of cannabis pure concentrates. Work-In-ProgressWork-in-progress consists of live plants grown for Edible Garden’s herb produce, and floral product lines along with IVXX’s line of cannabis pure concentrates.and live plants grown at Black Oak. Finished goods consists of Blum’s, MediFarm’s and IVXX’s line of cannabis packaged products to be sold into dispensaries, and Edible Garden’s products to the patientsbe sold via food, drug, and into dispensaries. mass channels.

Cost of goods sold is calculated using the average costing method. The Company reviews its inventory periodically to determine net realizable value.NRV. The Company writes down inventory, if required, based on forecasted demand. These factors are impacted by market and economic conditions, new products introductions, and require estimates that may include uncertain elements. Inventory at September

12
Table of Contents

NOTE 4 – INVENTORY (Continued)

As of June 30, 20162017 and December 31, 20152016, inventory consisted of the following:

 

 

September 30,

 

December 31,

 

 

June 30,

2017

 

 

December 31,

2016

 

 

2016

 

 

2015

 

 

 

 

 

 

 

Raw Materials

 

$576,508

 

$277,340

 

 

$1,010,401

 

$486,119

 

Work-In-Progress

 

419,432

 

542,530

 

Work-in-Progress

 

1,179,647

 

570,145

 

Finished Goods

 

 

1,472,159

 

 

 

129,578

 

 

 

1,043,024

 

 

 

853,066

 

 

$2,468,099

 

 

$949,448

 

 

 

 

 

 

Total Inventory

 

$3,233,072

 

 

$1,909,330

 

 

NOTE 65PROPERTY, EQUIPMENT AND LEASEHOLD IMPROVEMENTS

 

Property,As of June 30, 2017 and December 31, 2016, property, equipment and leasehold improvements at cost, less accumulated depreciation, at September 30, 2016 and December 31, 2015 consisted of the following:

 

 

 

September 30,

 

 

December 31,

 

 

 

2016

 

 

2015

 

Land

 

$702,020

 

 

$1,454,124

 

Furniture

 

 

507,182

 

 

 

70,786

 

Equipment

 

 

3,502,268

 

 

 

2,322,444

 

Leasehold improvements

 

 

7,236,177

 

 

 

3,893,330

 

Subtotal

 

 

11,947,647

 

 

 

7,740,684

 

Less accumulated depreciation

 

 

(2,142,743)

 

 

(1,045,709)

Total

 

$9,804,904

 

 

$6,694,975

 

 

 

June 30,

2017

 

 

December 31,

2016

 

 

 

 

 

 

 

 

Land and Building

 

$1,454,124

 

 

$1,454,124

 

Furniture and Equipment

 

 

3,376,758

 

 

 

3,141,244

 

Computer Hardware and Software

 

 

438,210

 

 

 

396,479

 

Leasehold Improvements

 

 

8,458,734

 

 

 

7,568,465

 

Construction in Progress

 

 

297,041

 

 

 

459,327

 

 

 

 

 

 

 

 

 

 

Subtotal

 

 

14,024,867

 

 

 

13,019,639

 

Less Accumulated Depreciation

 

 

(3,443,602)

 

 

(2,554,875)

 

 

 

 

 

 

 

 

 

Property, Equipment and Leasehold Improvements, Net

 

$10,581,265

 

 

$10,464,764

 

 

Depreciation expense related to property, equipment and leasehold improvements for the ninethree months ended SeptemberJune 30, 2017 and 2016 was $827,391$456,659 and $222,939, respectively, and for the yearsix months ended December 31, 2015June 30, 2017 and 2016 was $602,814.


17
Table of Contents

TERRA TECH CORP. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

Three$919,732 and Nine Months Ended September 30, 2016 and 2015$373,668, respectively.

 

NOTE 76INTANGIBLE ASSETS

As of June 30, 2017 and December 31, 2016, intangible assets consisted of the following:

 

 

 

 

 

June 30, 2017

December 31, 2016

 

 

 

Estimated Useful Life in Years

 

 

Gross
Carrying Amount

 

 

Accumulated Amortization

 

 

Net

Carrying Value

 

 

Gross
Carrying Amount

 

 

Accumulated Amortization

 

 

Net

Carrying
Value

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortized Intangible Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Customer Relationships

 

5 to 12

 

 

$8,960,700

 

 

$(1,218,528)

 

$7,742,172

 

 

$8,960,700

 

 

$(780,960)

 

$8,179,740

 

Trade Brands and Patent

 

2 to 8

 

 

 

498,598

 

 

 

(145,757)

 

 

352,841

 

 

 

498,598

 

 

 

(91,061)

 

 

407,537

 

Dispensary License

 

14

 

 

 

10,270,000

 

 

 

(916,965)

 

 

9,353,035

 

 

 

10,270,000

 

 

 

(550,179)

 

 

9,719,821

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Amortized Intangible Assets

 

 

 

 

 

 

19,729,298

 

 

 

(2,281,250)

 

 

17,448,048

 

 

 

19,729,298

 

 

 

(1,422,200)

 

 

18,307,098

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unamortized Intangible Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Trade Name

 

Indefinite

 

 

 

5,320,000

 

 

 

 

 

 

5,320,000

 

 

 

5,320,000

 

 

 

 

 

 

5,320,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Unamortized Intangible Assets

 

 

 

 

 

 

5,320,000

 

 

 

 

 

 

5,320,000

 

 

 

5,320,000

 

 

 

 

 

 

5,320,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Intangible Assets

 

 

 

 

 

$25,049,298

 

 

$(2,281,250)

 

$22,768,048

 

 

$25,049,298

 

 

$(1,422,200)

 

$23,627,098

 

 

Intangible assets with finite lives are amortized over their estimated useful lives. We recorded amortization expense of $826,400$429,525 and $42,480 during$516,878 for the ninethree months ended SeptemberJune 30, 2017 and 2016, respectively, and $859,050 and $527,498 for the yearsix months ended December 31, 2015,June 30, 2017 and 2016, respectively. Based solely on the amortizable intangible assets recorded at September 30, 2016, we estimate amortization expense to be $1,239,290 in 2016, $1,651,560 in 2017, $1,622,532 in 2018, $1,609,080 in 2019, $1,609,080 in 2020 and an aggregate of $13,719,270 in years after 2020. Actual amortization expense to be reported in future periods could differ from these estimates as a result of new intangible asset acquisitions, changes in useful lives or other relevant factors or changes.

 
13
Table of Contents

 

 

 

 

 

September 30, 2016

 

 

 

Useful

 

 

Gross

 

 

 

 

 

 

Life

 

 

Carrying

 

 

Accumulated

 

Amortized intangible assets:

 

in Years

 

 

Amount

 

 

Amortization

 

 

 

 

 

 

 

 

 

 

 

Customer Relationships

 

5 to 15

 

 

$8,693,200

 

 

$495,208

 

Trade Name

 

5 to 15

 

 

$4,666,898

 

 

$181,356

 

Dispensary License

 

15

 

 

$8,214,700

 

 

$263,824

 

Total

 

 

 

 

$21,574,798

 

 

$940,388

 

 

NOTE 87 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES

 

AccountsAs of June 30, 2017 and December 31, 2016, accounts payable and accrued expenses consisted of the following:

 

 

 

September 30,

 

 

December 31,

 

 

 

2016

 

 

2015

 

 

 

 

 

 

 

 

Accounts payable

 

$2,179,783

 

 

$1,105,994

 

Sales tax payable

 

 

226,319

 

 

 

-

 

Accrued expenses

 

 

3,734,367

 

 

 

-

 

Interest payable

 

 

246,390

 

 

 

103,465

 

 

 

$6,386,859

 

 

$1,119,459

 


18
Table of Contents

TERRA TECH CORP. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

Three and Nine Months Ended September 30, 2016 and 2015

 

 

June 30,

2017

 

 

December 31,

2016

 

 

 

 

 

 

 

 

Accounts Payable

 

$1,742,666

 

 

$1,986,907

 

Sales Tax Payable

 

 

360,176

 

 

 

122,470

 

Accrued Interest Payable

 

 

110,217

 

 

 

96,633

 

Accrued Expenses

 

 

1,313,439

 

 

 

211,390

 

 

 

 

 

 

 

 

 

 

Total Accounts Payable and Accrued Expenses

 

$3,526,498

 

 

$2,417,400

 

 

NOTE 98 – NOTES PAYABLE

 

Notes payable are as follows:

 

 

September 30,

 

 

December 31,

 

 

 

2016

 

 

2015

 

 

 

 

 

 

 

 

Promissory note dated July 25, 2014 issued to an accredited investor, which matured July 24, 2015 and bore interest at a rate of 12% per annum. The holder of the note extended the maturity to July 25, 2017. Principal and interest may be converted into common stock based on the average trading price of the ten days prior to maturity at the holder’s option.

 

$150,000

 

 

$150,000

 

 

 

 

 

 

 

 

 

 

Unsecured promissory demand notes issued to an accredited investor, which bears interest at a rate of 4% per annum. Holder may elect to convert into common stock at $0.75 per share. In 2015, the investor exchanged the notes from other accredited investors.

 

 

114,306

 

 

 

114,306

 

 

 

 

 

 

 

 

 

 

5% Original issue discount senior secured convertible promissory note dated May 5, 2014 issued to accredited investors, which matured November 5, 2015, and bore interest at a rate of 12% per annum. The fixed conversion price in effect was set at 90% of the 20-day volume weighted average price (“VWAP”) of our common stock on February 5, 2014, or $0.30753 per share. In 2015, the holder of the note converted some of the debt and accrued interest into common stock. The remaining balance of the note and accrued interest was converted into common stock in March 2016.

 

 

-

 

 

 

96,491

 

 

 

 

 

 

 

 

 

 

Convertible promissory note dated April 7, 2015 issued to accredited investors, which matures October 7, 2016 and bears interest at a rate of 12% per annum. The conversion price in effect is $0.1303, subject to adjustment. The remaining balance of the note and accrued interest was converted into common stock in January 2016.

 

 

-

 

 

 

170,856

 

 

 

 

 

 

 

 

 

 

Convertible promissory note dated May 13, 2015 issued to accredited investors, which matures November 13, 2016 and bears interest at a rate of 12% per annum. The conversion price in effect is $0.1211, subject to adjustment. The remaining balance of the note and accrued interest was converted into common stock in January 2016.

 

 

-

 

 

 

170,783

 

 

 

 

 

 

 

 

 

 

Convertible promissory note dated December 14, 2015, issued to accredited investors, which matures December 13, 2016 and bears interest at a rate of 12% per annum. The conversion price in effect is $0.1211, subject to adjustment.

 

 

439,381

 

 

 

214,927

 

 

 

 

 

 

 

 

 

 

Convertible promissory note dated March 10, 2016, issued to accredited investors, which matures September 10, 2017 and bears interest at a rate of 1% per annum. The conversion price in effect is 90% of the average of the lowest three (3) VWAPs for the five (5) consecutive trading days prior to the conversion date.

 

 

1,250,000

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Convertible promissory note dated May 27, 2016, and amended on July 25, 2016 issued to accredited investors, which matures May 27, 2018 and bears interest at a rate of 12% per annum. The conversion price in effect is $0.35, subject to adjustment.

 

 

699,341

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Convertible promissory note dated July 25, 2016, issued to accredited investors, which matures July 25, 2018 and bears interest at a rate of 12% per annum. The conversion price in effect is $0.35, subject to adjustment.

 

 

84,185

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Convertible promissory note dated August 12, 2016, issued to accredited investors, which matures August 12, 2018 and bears interest at a rate of 12% per annum. The conversion price in effect is $0.35, subject to adjustment.

 

 

39,137

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Convertible promissory note dated September 1, 2016, issued to accredited investors, which matures September 1, 2018 and bears interest at a rate of 12% per annum. The conversion price in effect is $0.35, subject to adjustment.

 

 

13,292

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Total Debt

 

 

2,789,642

 

 

 

917,363

 

 

 

 

 

 

 

 

 

 

Less short-term portion

 

 

1,953,687

 

 

 

917,363

 

 

 

 

 

 

 

 

 

 

Long-term portion

 

$835,955

 

 

$0

 


19
Table of Contents

TERRA TECH CORP. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

Three and Nine Months Ended SeptemberAs of June 30, 2016 and 2015

NOTE 9 – NOTES PAYABLE (Continued)

Total debt as of September 30, 20162017 and December 31, 2015,2016, notes payable consisted of the following:

 

 

June 30,

2017

 

 

December 31,

2016

 

 

 

 

 

 

 

 

Unsecured promissory demand notes issued to an accredited investor, which bear interest at a rate of 4% per annum. Holder may elect to convert into common stock at $0.75 per share. The remaining balance of the note and accrued interest was converted into common stock in April 2017.

 

$

 

 

$64,324

 

Convertible promissory note dated December 14, 2015, issued to accredited investors, which matured December 13, 2016 and bears interest at a rate of 12% per annum. The holder of the note extended the maturity to December 13, 2017. The conversion price is $0.1211, subject to adjustment.

 

 

500,000

 

 

 

500,000

 

Senior convertible promissory note dated October 28, 2016, issued to accredited investors, which matures April 28, 2018 and bears interest at a rate of 1% per annum. The conversion price is 90% of the average of the lowest three (3) VWAPs for the five (5) consecutive trading days prior to the conversion date. The remaining balance of the note and accrued interest was converted into common stock in January 2017.

 

 

 

 

 

102,582

 

Senior convertible promissory note dated November 1, 2016, issued to accredited investors, which matures May 1, 2018 and bears interest at a rate of 12% per annum. The conversion price is $0.35, subject to adjustment.

 

 

75,705

 

 

 

31,615

 

Senior convertible promissory note dated December 16, 2016, issued to accredited investors, which matures June 16, 2018 and bears interest at a rate of 12% per annum. The conversion price is $0.27, subject to adjustment.

 

 

 

 

 

1,220,155

 

Senior convertible promissory note dated June 23, 2017, issued to accredited investors, which matures December 23, 2018 and bears interest at a rate of 12% per annum. The conversion price is $0.1362, subject to adjustment.

 

 

736,290

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Debt

 

 

1,311,995

 

 

 

1,918,676

 

 

 

 

 

 

 

 

 

 

Less Short-Term Portion

 

 

575,705

 

 

 

564,324

 

 

 

 

 

 

 

 

 

 

Long-Term Portion

 

$736,290

 

 

$1,354,352

 

As of June 30, 2017 and December 31, 2016, total debt was $2,789,642$1,311,995 and $917,363,$1,918,676, respectively, which included unamortized debt discount of $4,474,664$2,338,005 and $693,435,$4,295,648, respectively. The seniorSenior secured promissory notes are secured by shares of common stock. There was accrued interest payable of $91,527$110,217 and $96,633 as of SeptemberJune 30, 2016.2017 and December 31, 2016, respectively.

See “Note 16 – Subsequent Events” for additional disclosure regarding changes in notes payable subsequent to June 30, 2017.

14
Table of Contents

NOTE 8 – NOTES PAYABLE(Continued)

Securities Purchase Agreement Dated June 23, 2017 and 12% Senior Convertible Promissory Note Due December 23, 2018

On June 23, 2017, the Company entered into a Securities Purchase Agreement with an accredited investor pursuant to which the Company sold to the accredited investor a 12% Senior Convertible Promissory Note due December 23, 2018 (“Note A”) in the principal amount of $3,000,000 for a purchase price of $3,000,000 (“Offering A”). There were no fees or expenses deducted from the net proceeds received by the Company in Offering A. Note A and the shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) issuable upon conversion of Note A are collectively referred to herein as the “Securities.”

All principal and interest due and owing under Note A is convertible into shares of Common Stock at any time at the election of the holder at a conversion price per share equal to the lower of (i) $0.1362 or (ii) 85% of the lowest daily volume weighted average price of the Common Stock in the fifteen (15) trading days prior to the conversion date (“Conversion Price A”), which Conversion Price A is subject to adjustment for (i) stock splits, stock dividends, combinations, or similar events and (ii) full ratchet anti-dilution protection. Upon certain events of default, the conversion price of Note A will automatically become 70% of the average of the three (3) lowest volume weighted average prices of the Common Stock in the twenty (20) consecutive trading days prior to the conversion date for so long as such event of default remains in effect.

In addition, at any time that (i) the daily volume weighted average price of the Common Stock for the prior ten (10) consecutive trading days is $0.70 or more and (ii) the average daily trading value of the Common Stock is greater than $2,500,000 for the prior ten (10) consecutive trading days, then the Company may demand, upon one (1) day’s notice, that the holder convert Note A at Conversion Price A.

The Company may prepay in cash any portion of the outstanding principal amount of Note A and any accrued and unpaid interest by, upon ten (10) days’ written notice to the holder, paying an amount equal to (i) 110% of the sum of the then-outstanding principal amount of Note A plus accrued but unpaid interest, if the prepayment date is within 90 days of the issuance date of Note A; (ii) 115% of the sum of the then-outstanding principal amount of Note A plus accrued but unpaid interest, if the prepayment date is between 91 days and 180 days of the issuance date of Note A; or (iii) 125% of the sum of the then-outstanding principal amount of Note A plus accrued but unpaid interest, if the prepayment date is after 180 days of the issuance date of Note A.

Securities Purchase Agreement Dated February 22, 2017 and 12% Senior Convertible Promissory Note Due August 22, 2018

On February 22, 2017, the Company entered into a Securities Purchase Agreement with an accredited investor pursuant to which the Company sold to the accredited investor a 12% Senior Convertible Promissory Note due August 22, 2018 (“Note B”) in the principal amount of $3,000,000 for a purchase price of $3,000,000 (“Offering B”). There were no fees or expenses deducted from the net proceeds received by the Company in Offering B. Note B and the shares of the Common Stock issuable upon conversion of Note B are collectively referred to herein as the “Securities.”

All principal and interest due and owing under Note B is convertible into shares of Common Stock at any time at the election of the holder at a conversion price per share equal to the lower of (i) $0.2495 or (ii) 85% of the lowest daily volume weighted average price of the Common Stock in the fifteen (15) trading days prior to the conversion date (“Conversion Price B”), which Conversion Price B is subject to adjustment for (i) stock splits, stock dividends, combinations, or similar events and (ii) full ratchet anti-dilution protection. Upon certain events of default, the conversion price of Note B will automatically become 70% of the average of the three (3) lowest volume weighted average prices of the Common Stock in the twenty (20) consecutive trading days prior to the conversion date for so long as such event of default remains in effect. All interest payments under the Note are payable, at the Company’s option, in cash or shares of Common Stock.

15
Table of Contents

NOTE 8 – NOTES PAYABLE(Continued)

In addition, at any time that (i) the daily volume weighted average price of the Common Stock for the prior ten (10) consecutive trading days is $0.70 or more and (ii) the average daily trading value of the Common Stock is greater than $2,500,000 for the prior ten (10) consecutive trading days, then the Company may demand, upon one (1) day’s notice, that the holder convert Note B at Conversion Price B.

The Company may prepay in cash any portion of the outstanding principal amount of Note B and any accrued and unpaid interest by, upon ten (10) days’ written notice to the holder, paying an amount equal to (i) 110% of the sum of the then-outstanding principal amount of Note B plus accrued but unpaid interest, if the prepayment date is within 90 days of the issuance date of Note B; (ii) 115% of the sum of the then-outstanding principal amount of Note B plus accrued but unpaid interest, if the prepayment date is between 91 days and 180 days of the issuance date of Note B; or (iii) 125% of the sum of the then-outstanding principal amount of Note B plus accrued but unpaid interest, if the prepayment date is after 180 days of the issuance date of Note B.

 

NOTE 109 – CONTINGENT CONSIDERATION LIABILITY

 

The Company accounts for “contingent consideration” according to FASB ASC 805, Business CombinationsCombinations” (“FASB ASC 805”). Contingent consideration typically represents the acquirer’s obligation to transfer additional assets or equity interests to the former owners of the acquiree if specified future events occur or conditions are met. FASB ASC 805 requires that contingent consideration be recognized at the acquisition-date fair value as part of the consideration transferred in the transaction. FASB ASC 805 uses the fair value definition in Fair Value Measurements, which defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As defined in FASB ASC 805, contingent consideration is (i) an obligation of the acquirer to transfer additional assets or equity interests to the former owners of an acquiree as part of the exchange for control of the acquire, if specified future events occur or conditions are met or (ii) the right of the acquirer to the return of previously transferred consideration, if specified conditions are met.


20
Table of Contents

 

TERRA TECH CORP. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

Three and Nine Months Ended September 30, 2016 and 2015

NOTE 10 – CONTINGENT CONSIDERATION LIABILITY (Continued)

Accordingly,In the acquisition of Black Oak, the Company valued the Holdback Consideration and the Performance-based Cash Consideration (collectively, the “Contingent Consideration”),contingent consideration based on an analysis using a cash flow model to determine the expected contingent consideration payment, which model determined that the aggregate expected contingent consideration liability was $15,305,463 and the present value of the contingent consideration liability was $12,754,553. Accordingly, the Company recognized at April 1, 2016, the closing date of the Black Oak merger, a $12,754,553 contingent consideration liability associated with the Contingent Considerationcontingent consideration paid pursuant to the Merger Agreement.

 

In determiningOn April 1, 2017, the likelihoodanniversary date of payouts related to the Contingent Consideration,acquisition and the probabilities for various scenarios (e.g., a 75% probability thatsettlement date of the maximum amountcontingent consideration, the final contingent consideration was approximately $16.5 million. A summary of Contingent Consideration will be payable),the changes in the contingent consideration as well as the discount rate useddetail is below:

 

 

Amount

 

 

 

 

 

Contingent Consideration Summary

 

 

 

 

 

 

 

Balance at December 31, 2016

 

$12,085,859

 

Change in Fair Market Valuation of Contingent Consideration

 

 

4,348,761

 

 

 

 

 

 

Balance at March 31, 2017 and April 1, 2017

 

$16,434,620

 

 

 

 

 

 

Contingent Consideration Detail

 

 

 

 

 

 

 

 

 

Performance-Based Cash Contingent Consideration

 

$2,088,000

 

Market-Based Stock Contingent Consideration

 

 

14,346,620

 

 

 

 

 

 

 

 

$16,434,620

 

Changes in the Company’s calculations were basedfair market valuation of the contingent consideration are recognized in the consolidated statements of operations. For the three and six months ended June 30, 2017, the loss on internal projections, allfair market valuation of which were vetted by the Company’s senior management.contingent consideration was $77,286, and $4,426,047, respectively.

16
Table of Contents

 

NOTE 9 – CONTINGENT CONSIDERATION LIABILITYHoldback Consideration(Continued)

 

The Holdback Consideration is comprisedDuring April 2017, in final settlement of (i) the market-based clawback amount (the “Market-Based Clawback Amount”) and (ii)contingent consideration, the performance-based clawback amount (the “Performance-Based Clawback Amount”). The Holdback Consideration, which is comprised ofCompany issued approximately $4.7 million in shares of our preferredits common stock, was issued on April 1, 2016, the closing dateor common stock equivalent of the Black Oak merger,approximately 18.1 million shares of its common stock, and will be held in an escrow account formade a periodcash payment of one year.

The Market-Based Clawback Amountapproximately $2.1 million. A summary is determined as follows:

 

a)

If the Terra Tech Common Stock 30-day VWAP on the one-year anniversary date of the Merger Agreement exceeds the Terra Tech Closing Price, the Market-Based Clawback Amount shall mean the number of shares of Terra Tech Common Stock equal to (i) (A) $4,912,000.00 divided by (B) the Terra Tech Closing Price, less (ii) (A) $4,912,000.00 divided by (B) the Terra Tech Common Stock 30-day VWAP on such date.

b)

If the Terra Tech Common Stock 30-day VWAP on the one-year anniversary date of the Merger Agreement is less than or equal to the Terra Tech Closing Price, the Market-Based Clawback Amount shall be zero shares.

In no event will the Market-Based Clawback Amount exceed 50% of the Holdback Consideration.


21
Table of Contents

TERRA TECH CORP. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

Three and Nine Months Ended September 30, 2016 and 2015

NOTE 10 – CONTINGENT CONSIDERATION LIABILITY (Continued)

The Performance-Based Clawback Amount is determined as follows:

a)

The “Lower Threshold” means an amount equal to $11,979,351.00, and the “Upper Threshold” means an amount equal to $16,667,000.00.

b)

If Black Oak’s operating revenues for the 12-month period following the closing date of the Black Oak merger (the “Year 1 Revenue”) is less than the Lower Threshold, then the Performance-Based Clawback Amount will be the number of shares obtained from a quotient, (A) the numerator of which is equal to the sum of (1) $4,912,000.00, plus (2) the product of 1.5 multiplied by the difference between the Lower Threshold and the Year 1 Revenue, and (B) the denominator of which is the Terra Tech common stock 30-day VWAP as of the one-year anniversary date of the closing of the Black Oak merger.

c)

If the Year 1 Revenue is greater than or equal to the Lower Threshold but is less than the Upper Threshold, then the Performance-Based Clawback Amount will be the number of shares obtained from a quotient, (A) the numerator of which is equal to the product of 1.053 multiplied by the difference between the Upper Threshold and the Year 1 Revenue, and (B) the denominator of which is the Terra Tech common stock 30-day VWAP as of the one-year anniversary date of the closing of the Black Oak merger.

d)

If the Year 1 Revenue is greater than or equal to the Upper Threshold, then the Performance-Based Clawback Amount will be zero shares

Performance-Based Cash Consideration

Contingent Consideration Balance at March 31, 2017

 

$16,434,620

 

 

 

 

 

 

Change in Fair Market Valuation of Contingent Consideration

 

 

77,286

 

Payment of Contingent Consideration in Cash

 

 

(2,088,000)

Settlement of Contingent Consideration

 

 

(4,739,638)

Settlement of Contingent Consideration Recorded Against Additional Paid-In Capital

 

 

(4,692,697)

Gain on Settlement of Contingent Consideration

 

 

(4,991,571)

 

 

 

 

 

Contingent Consideration Balance at June 30, 2017

 

$

 

 

Pursuant to the terms of the contingent consideration as outlined in the Merger Agreement, the Group B Shareholders may receive cash considerationCompany was required to release from escrow shares worth approximately $14.4 million. Of those shares, 18.1 million shares, with a value of up to approximately $2,088,000 to be paid on approximately the one-year anniversary date$4,789,638, were issued in final settlement of the closingMarket-Based Contingent Consideration, and approximately 34.2 million shares were additionally clawed-back. The Market-Based Clawback associated with common stock equivalent of the Black Oak merger, to be determined as follows:

(a)

$0 if Year 1 Revenue is less than or equal to $12,000,000; and

(b)

the product obtained by multiplying 0.447 times Year 1 Revenue if Year 1 Revenue is greater than $12,000,000; provided, that in no event will the Performance-based Cash Consideration amount exceed $2,088,000.

For example,approximately 35.1 million shares were clawed-back pursuant to the above formula, ifappreciation of the revenuequoted price of the Company’s stock underlying the market-based component of the contingent consideration. An additional common stock equivalent of approximately 34.2 million shares, with a value of $9,684,268, were clawed-back pursuant to disputes between the sellers of Black Oak and the Company with respect to certain operational and performance goals that would have impacted the appreciation of the quoted price of the Company’s common stock underlying the market-based component of the contingent consideration and, in Year 1 equals $16,666,666, theneffect, increasing the Performance-based Cash Consideration will be $2,088,000 calculated as follows:number of clawback shares. For the three and six months ended June 30, 2017, the Company recognized a gain on settlement of contingent consideration of $4,991,571. The balance attributable to related parties was recorded in additional paid in capital. 

   

Year 1 Revenue

 

$16,666,666

 

Less:

 

$12,000,000

 

 

 

$4,666,666

 

 

 

 

0.44742864

 

Performance-based Cash Payment

 

$2,088,000

 


See “Note 10 – Fair Value Measurements” for further information.

 
22
17
Table of Contents

TERRA TECH CORP. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

Three and Nine Months Ended September 30, 2016 and 2015

NOTE 10 – CONTINGENT CONSIDERATION LIABILITY (Continued)

The Contingent Consideration at September 30, 2016 was based upon the following formula:

 

 

 

 

 

One-year  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Anniversary

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Date of the

 

 

Value of

 

 

Performance-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Merger 30-

 

 

Common

 

 

Based

 

 

 

 

 

Probability-Weighted Amounts

 

 

 

 

Year 1
Revenue

 

 

 

 

 Day
VWAP
 

 

 

Stock to
Issue
 

 

 

Cash
Payment
 

 

 

Probability 

 

 

Earn-out
Shares
 

 

 

Performance-Based Cash 

 

 

Total 

 

 

 

 

 

 

 

5%

 

$14,262,022

 

 

$2,088,000

 

 

 

4.0%

 

$570,481

 

 

$83,520

 

 

$654,001

 

 

 

 

 

 

$0.2811

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Upside

 

 

80%

 

 

15%

 

$13,060,699

 

 

$2,088,000

 

 

 

12.0%

 

$1,567,284

 

 

$250,560

 

 

$1,817,844

 

$

16,667,000

 

 

 

 

$0.3811

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

80%

 

$12,358,783

 

 

$2,088,000

 

 

 

64.0%

 

$7,909,621

 

 

$1,336,320

 

 

$9,245,941

 

 

 

 

 

 

 

$0.4811

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

5%

 

$11,321,432

 

 

$747,500

 

 

 

0.8%

 

$84,911

 

 

$5,606

 

 

$90,517

 

 

 

 

 

 

 

$0.2811

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Base

 

 

15%

 

 

15%

 

$10,891,714

 

 

$747,500

 

 

 

2.3%

 

$245,064

 

 

$16,819

 

 

$261,882

 

$

13,670,835

 

 

 

 

$0.3811

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

80%

 

$10,640,637

 

 

$747,500

 

 

 

12.0%

 

$1,276,876

 

 

$89,700

 

 

$1,366,576

 

 

 

 

 

 

 

$0.4811

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

5%

 

$7,859,732

 

 

$0

 

 

 

0.3%

 

$19,649

 

 

$0

 

 

$19,649

 

 

 

 

 

 

 

$0.2811

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Downside

 

 

5%

 

 

15%

 

$8,338,359

 

 

$0

 

 

 

0.8%

 

$62,538

 

 

$0

 

 

$62,538

 

$

10,674,670

 

 

 

 

$0.3811

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

80%

 

$8,618,014

 

 

$0

 

 

 

4.0%

 

$344,721

 

 

$0

 

 

$344,721

 

 

 

 

 

 

 

$0.4811

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair Value of Expected Earn-out Payment

 

 

$12,081,144

 

 

$

1,782,525

$

13,863,669

 

 

 

 

 

 

 

 

 

 

Price per common Shares

 

 

$

0.2620 

 

 

$

0.2620

 

 

 

 

 

 

 

 

 

 

Discount rate

 

 

20 

 

 

 

20

 

 

 

 

 

 

 

 

 

 

Periods (nper)

 

 

 

0.500 

 

 

$

0.500

 

 

 

 

 

 

 

 

 

 

Payments

 

 

$

 

 

$

0

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Present value factor at 20% discount rate for 12 months

 

 

 

0.9129 

 

 

 

0.9129

 

 

 

 

 

 

 

 

 

 

Present value of contingent consideration

 

 

$

11,028,525 

 

 

$

1,627,216

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Present value of contingent consideration

 

 

 

 

 

$

12,655,741

 

23
Table of Contents

TERRA TECH CORP. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

Three and Nine Months Ended September 30, 2016 and 2015

 

NOTE 1110 – FAIR VALUE MEASUREMENTS

 

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table representstables set forth the fair value hierarchy for those financial assetsliabilities measured at fair value on a recurring basis:basis by level within the fair value hierarchy as of the dates indicated:

 

 

 

Fair Value at

 

 

 

 

 

 

 

 

 

 

 

 

September 30,

 

 

Fair Value Measurement Using

 

 

 

2016

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Derivative Liability - Conversion Feature

 

$6,895,000

 

 

 

-

 

 

 

-

 

 

$6,895,000

 

 

 

$6,895,000

 

 

 

-

 

 

 

-

 

 

$6,895,000

 

 

Fair Value at

June 30,

 

 

Fair Value Measurement Using

 

Description

 

2017

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Derivative Liabilities – Conversion Feature

 

$3,163,000

 

 

$

 

 

$

 

 

$3,163,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$3,163,000

 

 

$

 

 

$

 

 

$3,163,000

 

 

 

Fair Value at

 

 

 

 

 

 

 

 

 

 

 

 

December 31,

 

 

Fair Value Measurement Using

 

 

 

2015

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Derivative Liability - Conversion Feature

 

$743,400

 

 

 

-

 

 

 

-

 

 

$743,400

 

 

 

$743,400

 

 

 

-

 

 

 

-

 

 

$743,400

 


 

 

Fair Value at December 31,

 

 

Fair Value Measurement Using

 

Description

 

2016

 

 

Level 1

 

Level 2

 

 

Level 3

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Derivative Liabilities – Conversion Feature

 

$6,987,000

 

$

 

$

 

 

$6,987,000

 

Liability – Contingent Consideration

 

$

12,085,859

 

 

 

 

 

 

 

12,085,859

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$19,072,859

 

$

 

$

 

 

$19,072,859

 

 

LiabilitiesNo financial assets were measured on a recurring basis as of June 30, 2017 and December 31, 2016.

The following table presents a reconciliation of the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3): for the six months ended June 30, 2017:

 

Balance at December 31, 2015

 

$743,400

 

Change in fair market value of conversion feature

 

 

595,700

 

Issuance of equity instruments with debt greater than debt carrying amount

 

 

1,355,000

 

Derivative debt converted into equity

 

 

(570,100)

Issuance of equity instruments with derivatives

 

 

4,771,000

 

Balance at September 30, 2016

 

$6,895,000

 


Balance at December 31, 2016

 

$6,987,000

 

 

 

 

 

 

Change in Fair Market Value of Conversion Feature

 

 

(2,597,950)

Derivative Debt Converted into Equity

 

 

(5,672,050)

Issuance of Debt Instruments with Derivatives

 

 

4,446,000

 

 

 

 

 

 

Balance at June 30, 2017

 

$3,163,000

 

The following table presents a reconciliation of the contingent consideration liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the six months ended June 30, 2017:

Balance at December 31, 2016

 

$12,085,859

 

 

 

 

 

 

Change in Fair Market Valuation of Contingent Consideration

 

 

4,426,047

 

Payment of Contingent Consideration in Cash

 

 

(2,088,000)

Settlement of Contingent Consideration

 

 

(4,739,638)

Settlement of Contingent Consideration Recorded Against Additional Paid-In Capital

 

 

(4,692,697)

Gain on Settlement of Contingent Consideration

 

 

(4,991,571)

 

 

 

 

 

Balance at June 30, 2017

 

$

 

Non-Financial Assets Measured at Fair Value on a Non-Recurring Basis

Non-financial assets, such as property, equipment and leasehold improvements, goodwill, and intangible assets, are required to be measured at fair value only when an impairment loss is recognized. The Company did not record an impairment charge related to these assets during the three and six months ended June 30, 2017 and 2016.

 
24
18
Table of Contents

TERRA TECH CORP. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

Three and Nine Months Ended September 30, 2016 and 2015

 

NOTE 1211 – INCOME TAXES

 

The

For the three and six months ended June 30, 2017 and 2016, the Company had no income tax expense (benefit) for.

As of June 30, 2017 and December 31, 2016, the components of deferred income taxes consiststax assets and deferred income tax liabilities consisted of the following:

 

 

 

September 30,
2016

 

 

December 31,
2015

 

 

 

 

 

 

 

 

Current:

 

 

 

 

 

 

Federal

 

$742,300

 

 

$-

 

State

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

742,300

 

 

 

-

 

Deferred:

 

 

 

 

 

 

 

 

Federal

 

 

49,000

 

 

 

44,000

 

State

 

 

-

 

 

 

-

 

Total

 

$791,300

 

 

$44,000

 

 

 

June 30,

2017

 

 

December 31,

2016

 

 

 

 

 

 

 

 

Deferred Income Tax Assets:

 

 

 

 

 

 

Warrants Expense

 

$4,832,000

 

 

$4,186,000

 

Derivatives Expense

 

 

6,443,000

 

 

 

4,067,000

 

Net Operating Losses

 

 

19,105,000

 

 

 

15,242,000

 

 

 

 

 

 

 

 

 

 

Deferred Income Tax Liabilities:

 

 

 

 

 

 

 

 

Depreciation

 

 

(1,818,000)

 

 

(1,334,000)

 

 

 

 

 

 

 

 

 

Total

 

 

28,562,000

 

 

 

22,161,000

 

Valuation Allowance

 

 

(28,562,000)

 

 

(22,161,000)

 

 

 

 

 

 

 

 

 

Net Deferred Tax Liabilities

 

$

 

 

$

 

 

The componentsFor the three and six months ended June 30, 2017 and 2016, certain of deferred tax assetsthe Company’s subsidiaries produced and liabilities are as follows:sold cannabis or cannabis pure concentrates, subjecting the Company to the limits of IRC Section 280E. Pursuant to IRC Section 280E, the Company is allowed only to deduct expenses directly related to sales of product.

 

 

September 30,
2016

 

 

December 31,
2015

 

Deferred income tax assets:

 

 

 

 

 

 

Allowance for bad debt

 

$70,000

 

 

$74,000

 

Warrants and interest expense

 

 

4,002,000

 

 

 

3,412,000

 

Derivatives expense

 

 

1,992,000

 

 

 

729,000

 

Net operating loss

 

 

9,353,000

 

 

 

7,029,000

 

 

 

 

 

 

 

 

 

 

 

 

 

15,417,000

 

 

 

11,244,000

 

Deferred income tax liabilities:

 

 

 

 

 

 

 

 

Depreciation

 

 

(194,900)

 

 

(44,000)

 

 

 

 

 

 

 

 

 

Total

 

 

15,222,100

 

 

 

11,200,000

 

 

 

 

 

 

 

 

 

 

Valuation allowance

 

 

(15,417,000)

 

 

(11,244,000)

 

 

 

 

 

 

 

 

 

Net deferred tax assets (liabilities)

 

$(194,900)

 

$(44,000)

 

Permanent differences include ordinary and necessary business expenses deemed by the Company as a non-allowable deduction under Internal Revenue CodeIRC Section 280E, and tax deductions related to equity compensation that are less than the compensation recognized for financial reporting.


25
Table of Contents

TERRA TECH CORP. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

Three and Nine Months Ended September 30, 2016 and 2015

NOTE 12 – INCOME TAXES (Continued)

 

As of SeptemberJune 30, 2016,2017 and December 31, 2015,2016, the Company had net operating loss carryforwards of approximately $26,700,000$42,623,000 and $18,600,000,$34,940,000, respectively, which, if unused, will expire beginning in yearsthe year 2034. These tax attributes are subject to an annual limitation from equity shifts, which constitute a change of ownership as defined under Internal Revenue Code (“IRC”) Section 382, which will limit their utilization. The Company has yet to assess the effect of these limitations, but expects these losses to be substantially limited. Accordingly, the Company has placed a reserve against any assets associated with these losses.

The Company files income tax returns in the U.S. federal jurisdiction and various state and local jurisdictions. All tax years from 2012 to 2015 are subject to examination.

 

Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative losses incurred through the period ended SeptemberJune 30, 2016.2017. Such objective evidence limits the ability to consider other subjective evidence such as our projections for future growth. On the basis of this evaluation, as of SeptemberJune 30, 2016,2017, a valuation allowance of has been recorded against all deferred tax assets as these assets are more likely than not to be unrealized. The amount of the deferred tax asset considered realizable, however, could be adjusted if estimates of future taxable income during the carryforward period are reduced or increased or if objective negative evidence in the form of cumulative losses is no longer present and additional weight may be given to subjective evidence such as our projections for growth.

 

For the three quarters ended September 30, 2016, IVXX produced and sold cannabis pure concentrates, both Black Oak and MediFarm operated medical marijuana dispensaries, subjecting the Company to the limits of Internal Revenue Code Section 280E. Pursuant to IRC Section 280E, the Company is allowed only to deduct expenses directly related to sales of product. For the nine months ended September 30, 2016, the income tax expense is the tax on the gross sales in excess of direct costs that subject the Company to federal income tax pursuant to IRC Section 280E. The Company recorded a deferred tax liability related to the tax depreciation related to its cannabis operations in excess of that reported for financial reporting purposes.
19
Table of Contents

 

NOTE 1312CAPITAL STOCKEQUITY

 

Preferred Stock

 

The Company authorized 50 million shares of preferred stock with $0.001 par value. The Company designated 100 shares of preferred stock as “Series A Preferred Stock,” of which there were 100 shares of Series A Preferred Stock outstanding as of September 30, 2016. Series A Preferred Stock is convertible on a one-for-one basis into common stock and has all of the voting rights of the Company’s common stock.

 

The Company designated 49,990,900 shares of preferred stock as “Series B Preferred Stock,” of which there were 40,382,962 shares of Series B Preferred Stock outstanding as of September 30, 2016. Each share of Series B Preferred Stock: (i) is entitled to 100 votes for each share of common stock into which a sharesshare of Series B Preferred Stock is convertible and (ii) is convertible, at the option of the holder, on a 1-for-5.384325537 basis, into shares of the Company’s common stock.

 

See Common“Note 16 – Subsequent Events” for additional disclosure regarding changes to the Company’s Series B Preferred Stock subsequent to June 30, 2017.

 

TheDuring the six months ended June 30, 2017, the Company authorized 990 millionissued 600,000 shares of Series B Preferred Stock for compensation in the amount of $1,035,406.

During the six months ended June 30, 2017, the Company cancelled 4,279,841 shares of Series B Preferred Stock that had been previously issued and held in escrow in connection with the contingent consideration related to the Black Oak acquisition. See “Note 9 – Contingent Consideration Liability” for further information.

Common Stock

During the six months ended June 30, 2017, senior secured convertible promissory notes and accrued interest in the amount of $8,839,084 were converted into 50,710,473 shares of common stock.

During the six months ended June 30, 2017, the Company issued 17,674,027 shares of common stock $0.001 par value per share. Asfor cash in the amount of September$3,750,000 pursuant to an equity financing facility with an accredited investor.

During the six months ended June 30, 2016, 473,917,2772017, the Company issued 1,215,909 shares of common stock werefor director fees in the amount of $221,973, issued 2,859,005 shares of common stock for services performed in the amount of $591,359 and issued 1,635,780 shares of common stock for compensation in the amount of $320,732.

During the six months ended June 30, 2017, the Company cancelled 9,291,744 shares of common stock that had been previously issued and outstanding.held in escrow in connection with the contingent consideration related to the Black Oak acquisition. See “Note 9 – Contingent Consideration Liability” for further information.


During the six months ended June 30, 2016, senior secured convertible promissory notes and accrued interest in the amount of $961,740 were converted into 13,906,149 shares of common stock.

During the six months ended June 30, 2016, the Company sold 25,715,674 shares of common stock for the net amount of $3,208,134 pursuant to an equity financing facility with an accredited investor.

 
26
20
Table of Contents

 

TERRA TECH CORP. AND SUBSIDIARIESNOTE 12 – EQUITY (Continued)

Notes to Condensed Consolidated Financial Statements (Unaudited)

ThreeStock-Based Compensation Expense

A summary of stock-based compensation for the three months ended June 30, 2017 and Nine Months Ended September2016 is as follows:

 

 

For the Three Months Ended

 

 

 

June 30, 2017

 

 

June 30, 2016

 

Type of Award

 

Number of Shares or Options Granted

 

 

Stock-Based Compensation Expense

 

 

Number of Shares or Options Granted

 

 

Stock-Based Compensation Expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock Options

 

 

8,250,000

 

 

$157,430

 

 

 

 

 

$47,589

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock Grants:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Employees (Common Stock)

 

 

1,535,780

 

 

 

294,632

 

 

 

 

 

 

 

Employees (Series B Preferred Stock)

 

 

 

 

 

 

 

 

 

 

 

 

Directors (Common Stock)

 

 

1,090,909

 

 

 

184,473

 

 

 

 

 

 

 

Non–Employee Consultants (Common Stock)

 

 

2,391,358

 

 

 

446,348

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Stock-Based Compensation

 

 

13,268,047

 

 

$1,082,883

 

 

 

 

 

$47,589

 

A summary of stock-based compensation for the six months ended June 30, 2017 and 2016 and 2015is as follows:

 

 

For the Six Months Ended

 

 

 

June 30, 2017

 

 

June 30, 2016

 

Type of Award

 

Number of
Shares or
Options
Granted

 

 

Stock-Based Compensation Expense

 

 

Number of
Shares or
Options
Granted

 

 

Stock-Based Compensation Expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock Options

 

 

8,250,000

 

 

$205,019

 

 

 

6,700,000

 

 

$95,178

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock Grants:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Employees (Common Stock)

 

 

1,635,780

 

 

 

320,732

 

 

 

 

 

 

 

Employees (Series B Preferred Stock)

 

 

600,000

 

 

 

1,035,406

 

 

 

 

 

 

 

Directors (Common Stock)

 

 

1,215,909

 

 

 

221,973

 

 

 

350,000

 

 

 

60,550

 

Non–Employee Consultants (Common Stock)

 

 

2,859,005

 

 

 

591,359

 

 

 

70,000

 

 

 

20,727

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Stock–Based Compensation

 

 

14,560,694

 

 

$2,374,489

 

 

 

7,120,000

 

 

$176,455

 

 

NOTE 14 – WARRANTS

The Company has the following shares of common stock reserved for exercise of the warrants outstanding as of September 30, 2016:

 

 

September 30, 2016

 

 

 

Shares

 

 

Weighted

Average

Exercise

Price

 

 

 

 

 

 

 

 

Warrants outstanding – beginning of year

 

 

32,426,008

 

 

$0.18

 

Warrants exercised

 

 

(26,251,785)

 

 

0.17

 

Warrants granted

 

 

10,395,675

 

 

 

0.22

 

Warrants expired

 

 

(523.333)

 

 

(0.45)

 

 

 

 

 

 

 

 

 

Warrants outstanding – end of period

 

 

16,046,565

 

 

$0.18

 

The following table summarizes information about fixed-price warrants outstanding:

Range of

 

 

Number

Outstanding at

 

 

Average

Remaining

 

Weighted

 

Exercise

 

 

September 30,

 

 

Contractual

 

Average

 

Prices

 

 

2016

 

 

Life

 

Exercise Price

 

 

 

 

 

 

 

 

 

 

 

$

0.33

 

 

 

439,637

 

 

4 Months

 

$0.33

 

$

0.16

 

 

 

750,000

 

 

6 Months

 

$0.16

 

$

0.14

 

 

 

1,578,947

 

 

21 Months

 

$0.14

 

$

0.21

 

 

 

400,644

 

 

21 Months

 

$0.21

 

$

0.14

 

 

 

1,846,300

 

 

22 Months

 

$0.14

 

$

0.06

 

 

 

4,567,002

 

 

24 Months

 

$0.06

 

$

0.16

 

 

 

1,118,068

 

 

29 Months

 

$0.16

 

$

0.13

 

 

 

863,392

 

 

30 Months

 

$0.13

 

$

0.12

 

 

 

928,984

 

 

32 Months

 

$0.12

 

$

0.35

 

 

 

1,625,000

 

 

45 Months

 

$0.35

 

$

0.35

 

 

 

535,714

 

 

47 Months

 

$0.35

 

$

0.44

 

 

 

1,214,286

 

 

47 Months

 

$0.44

 

$

0.37

 

 

 

178,571

 

 

48 Months

 

$0.37

 

 

 

 

 

 

16,046,545

 

 

 

 

 

 

 


27
Table of Contents

TERRA TECH CORP. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

Three and Nine Months Ended September 30, 2016 and 2015

NOTE 1513 – COMMITMENTS

 

The Company entered into an agreement with Platinum Standard, LLC (“Platinum”) to be the operator of Black Oak Gallery. Beginning on April 1, 2016 the Company will pay Platinum $500,000 for the first fiscal year, $550,000 for the second fiscal year and $600,000 for the third fiscal year.Operating Lease Commitments

 

The Company leases certain business facilities under operating lease agreements that specify minimum rentals. Many of these have renewal provisions along with the option to acquire the property.provisions. The Company’s net rent expense for the ninethree months ended SeptemberJune 30, 2017 and 2016 was $312,254 and 2015$298,092, respectively, and for the six months ended June 30, 2017 and 2016 was $627,067 and $431,959, and $379,166, respectively. Future minimum lease payments under non-cancelable

21
Table of Contents

NOTE 13 – COMMITMENTS (Continued)

Production Operating Agreement

On May 23, 2017, the Company entered into a one-year operating leases having an initial or remaining termagreement with Panther Gap Farms pursuant to which Panther Gap Farms will grow up to approximately one metric ton of more thanthe Company’s IVXX cannabis annually. The operating agreement is renewable for up to three additional terms of one year each. The agreement also requires the Company to issue common stock, with a value of $1,150,000, upon execution of the agreement, which the Company had not issued as of June 30, 2017. In addition to the common stock, the Company is required to issue common stock for the profit share of the cannabis ultimately sold by the Company upon execution of the agreement. The shares to be received by Panther Gap Farms under the profit share agreement are as follows:

 

 

Scheduled

 

Year Ending December 31:

 

Payments

 

 

 

 

 

2016

 

$541,656

 

2017

 

 

487,518

 

2018

 

 

478,587

 

2019

 

 

342,336

 

2020

 

 

256,173

 

2021 and thereafter

 

 

2,021,484

 

Total minimum rental payments

 

$4,127,754

 

NOTE 16 – LITIGATION AND CLAIMSdependent on the ultimate profit recognized by the Company when the cannabis product is sold. As of June 30, 2017, the Company has not issued the required shares.

 

The Company and Panther Gap Farms also entered into a lease agreement pursuant to which the Company leases the property on which the cannabis is grown. The lease agreement requires monthly payments of $30,000 for eight months and is also renewable for up to three additional terms of one year each.

NOTE 14 – SEGMENT INFORMATION

The Company’s operating and reportable segments are currently organized around the subjectfollowing products that it offers as part of lawsuitsits core business strategy:

·Herbs and Produce Products – Includes herbs and leafy greens that are grown using classic Dutch hydroponic farming methods.

·Cannabis Dispensary, Cultivation and Production – Includes cannabis-focused retail, cultivation and production.

These two reportable segments, which are described in greater detail below, had previously been reported on a combined basis as they had been operated and claims arisingevaluated as one operating segment. The Company experienced significant growth over the last few years in most of our product areas. As the Company has grown organically, and as the Company previously added to its capabilities through acquisitions, its products have increased in scale and become more strategically important and distinctly organized and managed under these two groupings. In addition, Derek Peterson, the Company’s Chief Operating Decision Maker (“CODM”), reviews results, manages and allocates resources between these two strategic business groupings, and budgets using these business segments. The Company’s CODM reviews revenues including intersegment revenues, gross profit and operating income (loss) before income taxes when evaluating segment performance and allocating resources to each segment. Accordingly, intersegment revenue is included in the ordinary coursesegment revenues presented in the tables below and is eliminated from revenues and cost of business from time to time.goods sold in the “Eliminations and Other” column. The Company reviews any such legal proceedings“Eliminations and claims on an ongoing basisOther” column also includes various income and follow appropriate accounting guidance when making accrual and disclosure decisions. The Company establishes accruals for those contingencies whereexpense items that the incurrence of a loss is probable and can be reasonably estimated, and it discloses the amount accrued and the amount of a reasonably possible loss in excess of the amount accrued, if such disclosure is necessary for the Company’s financial statements to not be misleading. To estimate whether a loss contingency should be accrued by a charge to income, the Company evaluates, among other factors, the degree of probability of an unfavorable outcome and the ability to make a reasonable estimate of the amount of the loss. The Company does not record liabilities whenallocate to its operating segments. These income and expense amounts include the likelihood thatresults of the liability has been incurred is probable, but the amount cannot be reasonably estimated. Based upon present information, the Company determined that there were no matters that required an accrualCompany’s hydroponic equipment, which are not material, interest income, interest expense, corporate overhead, and corporate-wide expense items such as of September 30, 2016, nor were there any asserted or unasserted claimslegal and professional fees as well as expense items for which material losseswe have not identified a reasonable basis for allocation. The accounting policies of the reportable segments are reasonably possible.the same as those described in “Note 2 - Summary of Significant Accounting Policies” of the Notes to Unaudited Consolidated Financial Statements.

Herbs and Produce Products

Either independently or in conjunction with third parties, we are a retail seller of locally grown hydroponic herbs, produce, and floral products, which are distributed through major grocery stores throughout the East and Midwest regions of the U.S.

22
Table of Contents

NOTE 14 – SEGMENT INFORMATION(Continued)

Cannabis Dispensary, Cultivation and Production

Either independently or in conjunction with third parties, we operate medical marijuana retail dispensaries, medical marijuana cultivation and production facilities in California and Nevada. We own real property in Nevada on which we plan to build a medical marijuana dispensary. All of our retail dispensaries in California and Nevada offer a broad selection of medical cannabis products including flowers, concentrates and edibles. We also produce and sell a line of medical cannabis flowers, as well as a line of medical cannabis-extracted products, which include concentrates, cartridges, vape pens and wax products.

Summarized financial information concerning the Company’s reportable segments is shown in the following tables. Total assets at June 30, 2017 and 2016 exclude intercompany receivable balances eliminated in consolidation.

 

 

For the Three Months Ended June 30, 2017

 

 

 

Herbs and Produce Products

 

 

Cannabis Dispensary, Cultivation and Production

 

 

Eliminations and Other

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Revenues

 

$1,777,067

 

 

$6,049,319

 

 

$16,487

 

 

$7,842,873

 

Cost of Goods Sold

 

 

1,325,729

 

 

 

5,010,771

 

 

 

 

 

 

6,336,500

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross Profit

 

 

451,338

 

 

 

1,038,548

 

 

 

16,487

 

 

 

1,506,373

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, General and Administrative Expenses

 

 

855,999

 

 

 

2,210,475

 

 

 

2,962,813

 

 

 

6,029,287

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from Operations

 

 

(404,661)

 

 

(1,171,927)

 

 

(2,946,326)

 

 

(4,522,914)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Income (Expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of Debt Discount

 

 

 

 

 

 

 

 

(515,654)

 

 

(515,654)

Loss on Extinguishment of Debt

 

 

 

 

 

 

 

 

(1,639,137)

 

 

(1,639,137)

Gain on Fair Market Valuation of Derivatives

 

 

 

 

 

 

 

 

987,200

 

 

 

987,200

 

Interest Expense

 

 

 

 

 

 

 

 

(130,510)

 

 

(130,510)

Loss on Fair Market Valuation of Contingent Consideration

(77,286

)

(77,286

)

Gain on Settlement of Contingent Consideration

4,991,571

4,991,571

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Other Income (Expense)

 

 

 

 

 

4,914,285

 

 

(1,298,101)

 

 

3,616,184

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss Before Provision for Income Taxes

 

$(404,661)

 

$3,742,358

 

 

$(4,244,427)

 

$(906,730)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Assets at June 30, 2017

 

$7,104,469

 

 

$60,224,138

 

 

$9,550,062

 

 

$76,878,669

 

 

 

For the Three Months Ended June 30, 2016

 

 

 

Herbs and Produce Products

 

 

Cannabis Dispensary, Cultivation and Production

 

 

Eliminations and Other

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Revenues

 

$5,873,418

 

 

$3,768,977

 

 

$57,514

 

 

$9,699,909

 

Cost of Goods Sold

 

 

5,517,052

 

 

 

2,596,035

 

 

 

39,848

 

 

 

8,152,935

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross Profit

 

 

356,366

 

 

 

1,172,942

 

 

 

17,666

 

 

 

1,546,974

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, General and Administrative Expenses

 

 

756,405

 

 

 

1,649,452

 

 

 

2,958,494

 

 

 

5,364,351

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from Operations

 

 

(400,039)

 

 

(476,510)

 

 

(2,940,828)

 

 

(3,817,377)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Income (Expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of Debt Discount

 

 

 

 

 

 

 

 

(218,126)

 

 

(218,126)

Loss from Derivatives Issued with Debt Greater than Debt Carrying Value

 

 

 

 

 

 

 

 

(488,000)

 

 

(488,000)

Loss on Fair Market Valuation of Derivatives

 

 

 

 

 

 

 

 

(206,000)

 

 

(206,000)

Interest Income (Expense)

 

 

 

 

 

250

 

 

 

(60,815)

 

 

(60,565)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Other Income (Expense)

 

 

 

 

 

250

 

 

 

(972,941)

 

 

(972,691)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss Before Provision for Income Taxes

 

$(400,039)

 

$(476,260)

 

$(3,913,769)

 

$(4,790,068)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Assets at June 30, 2016

 

$6,834,863

 

 

$57,142,755

 

 

$2,784,814

 

 

$66,762,432

 

23
Table of Contents

NOTE 14 – SEGMENT INFORMATION(Continued)

 

 

For the Six Months Ended June 30, 2017

 

 

 

Herbs and Produce Products

 

 

Cannabis Dispensary, Cultivation and Production

 

 

Eliminations and Other

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Revenues

 

$2,694,210

 

 

$11,936,357

 

 

$36,762

 

 

$14,667,329

 

Cost of Goods Sold

 

 

2,295,544

 

 

 

10,506,349

 

 

 

 

 

 

12,801,893

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross Profit

 

 

398,666

 

 

 

1,430,008

 

 

 

36,762

 

 

 

1,865,436

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, General and Administrative Expenses

 

 

1,515,062

 

 

 

4,837,480

 

 

 

6,063,045

 

 

 

12,415,587

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from Operations

 

 

(1,116,396)

 

 

(3,407,472)

 

 

(6,026,283)

 

 

(10,550,151)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Income (Expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of Debt Discount

 

 

 

 

 

 

 

 

(1,126,270)

 

 

(1,126,270)

Loss on Extinguishment of Debt

 

 

 

 

 

 

 

 

(2,678,595)

 

 

(2,678,595)

Gain on Fair Market Valuation of Derivatives

 

 

 

 

 

 

 

 

2,597,950

 

 

 

2,597,950

 

Interest Expense

 

 

 

 

 

 

 

 

(288,343)

 

 

(288,343)

Loss on Fair Market Valuation of Contingent Consideration

(4,426,047

)

(4,426,047

)

Gain on Settlement of Contingent Consideration

4,991,571

4,991,571

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Other Income (Expense)

 

 

 

 

 

565,524

 

 

 

(1,495,258)

 

 

(929,734

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss Before Provision for Income Taxes

 

$(1,116,396)

 

$(2,841,948

)

 

$(7,521,541)

 

$(11,479,885)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Assets at June 30, 2017

 

$7,104,469

 

 

$60,224,138

 

 

$9,550,062

 

 

$76,878,669

 

 

 

For the Six Months Ended June 30, 2016

 

 

 

Herbs and Produce Products

 

 

Cannabis Dispensary, Cultivation and Production

 

 

Eliminations and Other

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Revenues

 

$7,274,861

 

 

$3,899,180

 

 

$74,035

 

 

$11,248,076

 

Cost of Goods Sold

 

 

6,837,431

 

 

 

2,809,296

 

 

 

39,848

 

 

 

9,686,575

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross Profit

 

 

437,430

 

 

 

1,089,884

 

 

 

34,187

 

 

 

1,561,501

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, General and Administrative Expenses

 

 

1,155,610

 

 

 

1,851,588

 

 

 

4,284,054

 

 

 

7,291,252

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from Operations

 

 

(718,180)

 

 

(761,704)

 

 

(4,249,867)

 

 

(5,729,751)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Income (Expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of Debt Discount

 

 

 

 

 

 

 

 

(312,532)

 

 

(312,532)

Loss on Extinguishment of Debt

 

 

 

 

 

 

 

 

(920,797)

 

 

(920,797)

Loss from Derivatives Issued with Debt Greater than Debt Carrying Value

 

 

 

 

 

 

 

 

(488,000)

 

 

(488,000)

Loss on Fair Market Valuation of Derivatives

 

 

 

 

 

 

 

 

(1,366,700)

 

 

(1,366,700)

Interest Income (Expense)

 

 

 

 

 

250

 

 

 

(116,810)

 

 

(116,560)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Other Income (Expense)

 

 

 

 

 

250

 

 

 

(3,204,839)

 

 

(3,204,589)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss Before Provision for Income Taxes

 

$(718,180)

 

$(761,454)

 

$(7,454,706)

 

$(8,934,340)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Assets at June 30, 2016

 

$6,834,863

 

 

$57,142,755

 

 

$2,784,814

 

 

$66,762,432

 

24
Table of Contents

 

NOTE 1715SEGMENT INFORMATION

The Company’s operating and reportable segments are currently organized around the following products that it offers as part of its core business strategy:

·

Hydroponic Produce

·

Cannabis Products


28
Table of Contents

TERRA TECH CORP.LITIGATION AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

Three and Nine Months Ended September 30, 2016 and 2015

NOTE 17 – SEGMENT INFORMATION (Continued)

These two reportable segments, which are described in greater detail below, had previously been reported on a combined basis as they had been operated and evaluated as one operating segment. The Company experienced significant growth over the last year in most of our product areas. As the Company has grown organically, and as the Company previously added to its capabilities through acquisitions, its products have increased in scale and become more strategically important and distinctly organized and managed under these two groupings. In addition, Derek Peterson, the Company’s chief operating decision maker (“CODM”) has begun reviewing results and managing and allocating resources between these two strategic business groupings, and has begun budgeting using these business segments. The Company’s segment information for the nine months ended September 30, 2016 has been reclassified to conform to its current presentation.

The Company’s CODM reviews revenues including intersegment revenues, gross profit and operating income (loss) before income taxes when evaluating segment performance and allocating resources to each segment. Accordingly, intersegment revenue is included in the segment revenues presented in the tables below and is eliminated from revenues and cost of sales in the “Eliminations and Other” column. The “Eliminations and Other” column also includes various income and expense items that the Company does not allocate to its operating segments. These income and expense amounts include the results of the Company’s hydroponic equipment, which are not material, interest income, interest expense, corporate overhead, and corporate-wide expense items such as legal and professional fees as well as expense items for which we have not identified a reasonable basis for allocation. The accounting policies of the reportable segments are the same as those described in Note 1 of the Notes to the Consolidated Financial Statements.

Hydroponic Produce

The Company’s locally grown hydroponic produce, which include produce, herbs, and floral products, are started from seed and are grown in environmentally controlled greenhouses. When harvested, the products are sold through retailers targeted to customers seeking produce, herbs, or floral products locally grown using environmentally sustainable methods.

Cannabis ProductsCLAIMS

 

The Company currently operates or plansis the subject of lawsuits and claims arising in the ordinary course of business from time to operate medical marijuana cultivation, production, and dispensary facilities in California and Nevada through its subsidiaries, Black Oak Gallery, MediFarm, MediFarm I, and MediFarm II.time. The Company was granted eight provisional permitsreviews any such legal proceedings and claims on an ongoing basis and follows appropriate accounting guidance when making accrual and disclosure decisions. The Company establishes accruals for those contingencies where the incurrence of a loss is probable and can be reasonably estimated, and it discloses the amount accrued and the amount of a reasonably possible loss in Nevada and have received approval from the local authorities with respect to allexcess of the permits. IVXX’s cannabis products are currently produced inamount accrued, if such disclosure is necessary for the Company’s lab in Californiafinancial statements to not be misleading. To estimate whether a loss contingency should be accrued by a charge to income, the Company evaluates, among other factors, the degree of probability of an unfavorable outcome and are sold in select dispensaries throughout California.


29
Table of Contents

TERRA TECH CORP. AND SUBSIDIARIES

Notesthe ability to Condensed Consolidated Financial Statements (Unaudited)

Three and Nine Months Ended September 30, 2016 and 2015

NOTE 17 – SEGMENT INFORMATION (Continued)

Summarized financial information concerning the Company’s reportable segments is shown in the following tables. Total asset amounts at September 30, 2016 and 2015 exclude intercompany receivable balances eliminated in consolidation.

 

 

Three Months Ended September 30, 2016

 

 

 

Hydroponic

 

 

Cannabis

 

 

Eliminations

 

 

 

 

 

 

Produce

 

 

Products

 

 

and Other

 

 

Total

 

Total Revenues

 

$2,138,260

 

 

$4,769,912

 

 

$42,193

 

 

$6,950,365

 

Cost of Goods Sold

 

 

1,857,783

 

 

 

3,747,841

 

 

 

25,355

 

 

 

5,630,979

 

Gross Margin

 

 

280,477

 

 

 

1,022,071

 

 

 

16,838

 

 

 

1,319,386

 

Selling, general and administrative expenses

 

 

705,751

 

 

 

1,920,468

 

 

 

3,379,727

 

 

 

6,005,946

 

Loss from operations

 

 

(425,274)

 

 

(898,397)

 

 

(3,362,889)

 

 

(4,686,560)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Income (Expenses)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of debt discount

 

 

-

 

 

 

-

 

 

 

(610,089)

 

 

(610,089)

Loss on extinguishment of debt

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Loss from derivatives issued with debt greater than debt carrying value

 

 

-

 

 

 

-

 

 

 

(867,000)

 

 

(867,000)

Gain (Loss) on fair market valuation of derivatives

 

 

-

 

 

 

-

 

 

 

771,000

 

 

 

771,000

 

Interest Income (Expense)

 

 

-

 

 

 

(250)

 

 

(159,383)

 

 

(159,633)

Total Other Income (Expense)

 

 

-

 

 

 

(250)

 

 

(865,472)

 

 

(865,722)

Loss before Provision of Income Taxes

 

$(425,274)

 

$(898,647)

 

$(4,228,361)

 

$(5,552,282)

 

 

Three Months Ended September 30, 2015

 

 

 

Hydroponic

 

 

Cannabis

 

 

Eliminations

 

 

 

 

 

Produce

 

 

Products

 

 

and Other

 

 

Total

 

Total Revenues

 

$1,597,378

 

 

$420,973

 

 

$-

 

 

$2,018,351

 

Cost of Goods Sold

 

 

1,370,804

 

 

 

290,256

 

 

 

(12,515)

 

 

1,648,545

 

Gross Margin

 

 

226,574

 

 

 

130,717

 

 

 

12,515

 

 

 

369,806

 

Selling, general and administrative expenses

 

 

441,177

 

 

 

164,970

 

 

 

1,493,167

 

 

 

2,099,314

 

Loss from operations

 

 

(214,603)

 

 

(34,253)

 

 

(1,480,652)

 

 

(1,729,508)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Income (Expenses)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of debt discount

 

 

-

 

 

 

-

 

 

 

(258,306)

 

 

(258,306)

Loss on extinguishment of debt

 

 

-

 

 

 

-

 

 

 

(263,950)

 

 

(263,950)

Loss from derivatives issued with debt greater than debt carrying value

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Gain (Loss) on fair market valuation of derivatives

 

 

-

 

 

 

-

 

 

 

372,400

 

 

 

372,400

 

Interest Income (Expense)

 

 

-

 

 

 

-

 

 

 

(108,563)

 

 

(108,563)

Total Other Income (Expense)

 

 

-

 

 

 

-

 

 

 

(258,419)

 

 

(258,419)

Loss before Provision of Income Taxes

 

$(214,603)

 

$(34,253)

 

$(1,739,071)

 

$(1,987,927)

30
Table of Contents

TERRA TECH CORP. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

Three and Nine Months Ended September 30, 2016 and 2015

NOTE 17 – SEGMENT INFORMATION (Continued)

 

 

Nine Months Ended September 30, 2016

 

 

 

Hydroponic

 

 

Cannabis

 

 

Eliminations

 

 

 

 

 

 

Produce

 

 

Products

 

 

and Other

 

 

Total

 

Total Revenues

 

$9,413,121

 

 

$8,669,092

 

 

$116,228

 

 

$18,198,441

 

Cost of Goods Sold

 

 

8,472,797

 

 

 

6,557,137

 

 

 

65,203

 

 

 

15,095,137

 

Gross Margin

 

 

940,324

 

 

 

2,111,955

 

 

 

51,025

 

 

 

3,103,304

 

Selling, general and administrative expenses

 

 

2,083,778

 

 

 

3,772,056

 

 

 

7,663,781

 

 

 

13,519,615

 

Loss from operations

 

 

(1,143,454)

 

 

(1,660,101)

 

 

(7,612,756)

 

 

(10,416,311)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Income (Expenses)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of debt discount

 

 

-

 

 

 

-

 

 

 

(922,621)

 

 

(922,621)

Loss on extinguishment of debt

 

 

-

 

 

 

-

 

 

 

(920,797)

 

 

(920,797)

Loss from derivatives issued with debt greater than debt carrying value

 

 

-

 

 

 

-

 

 

 

(1,355,000)

 

 

(1,355,000)

Gain (Loss) on fair market valuation of derivatives

 

 

-

 

 

 

-

 

 

 

(595,700)

 

 

(595,700)

Interest Income (Expense)

 

 

-

 

 

 

-

 

 

 

(276,193)

 

 

(276,193)

Total Other Income (Expense)

 

 

-

 

 

 

-

 

 

 

(4,070,311)

 

 

(4,070,311)

Loss before Provision of Income Taxes

 

$(1,143,454)

 

$(1,660,101)

 

$(11,683,067)

 

$(14,486,622)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total assets at September 30, 2016

 

$6,725,967

 

 

$2,390,233

 

 

$60,849,033

 

 

$69,965,233

 

 

 

Nine Months Ended September 30, 2015

 

 

 

Hydroponic

 

 

Cannabis

 

 

Eliminations

 

 

 

 

 

 

Produce

 

 

Products

 

 

and Other

 

 

Total

 

Total Revenues

 

$6,832,805

 

 

$852,745

 

 

$120,444

 

 

$7,805,994

 

Cost of Goods Sold

 

 

6,266,858

 

 

 

569,417

 

 

 

108,584

 

 

 

6,944,859

 

Gross Margin

 

 

565,947

 

 

 

283,328

 

 

 

11,860

 

 

 

861,135

 

Selling, general and administrative expenses

 

 

1,373,976

 

 

 

721,104

 

 

 

5,697,365

 

 

 

7,792,445

 

Loss from operations

 

 

(808,029)

 

 

(437,776)

 

 

(5,685,505)

 

 

(6,931,310)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Income (Expenses)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of debt discount

 

 

-

 

 

 

-

 

 

 

(524,161)

 

 

(524,161)

Loss on extinguishment of debt

 

 

-

 

 

 

-

 

 

 

(263,950)

 

 

(263,950)

Loss from derivatives issued with debt greater than debt carrying value

 

 

-

 

 

 

-

 

 

 

(561,000)

 

 

(561,000)

Gain (Loss) on fair market valuation of derivatives

 

 

-

 

 

 

-

 

 

 

1,779,600

 

 

 

1,779,600

 

Interest Income (Expense)

 

 

-

 

 

 

-

 

 

 

(426,793)

 

 

(426,793)

Total Other Income (Expense)

 

 

-

 

 

 

-

 

 

 

3,696

 

 

 

3,696

 

Loss before Provision of Income Taxes

 

$(808,029)

 

$(437,776)

 

$(5,681,809)

 

$(6,927,614)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total assets at September 30, 2015

 

$5,645,677

 

 

$1,105,796

 

 

$1,887,156

 

 

$8,638,629

 


31
Table of Contents

TERRA TECH CORP. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

Three and Nine Months Ended September 30, 2016 and 2015

NOTE 18 – RELATED PARTY TRANSACTIONS

During the three months ended March 31, 2016, our subsidiary, IVXX, purchased raw materials totaling $16,076 from Black Oak, an entity in which the Company’s Chief Executive Officer then-held an ownership interest. On April 1, 2016, we completed the merger, whereby Merger Sub merged with and into Black Oak, with Black Oak as the surviving corporation, and becomingmake a wholly-owned subsidiaryreasonable estimate of the Company. The termsamount of the purchasesloss. The Company does not record liabilities when the likelihood that the liability has been incurred is probable, but the amount cannot be reasonably estimated. Based upon present information, the Company determined that there were no matters that required an accrual as of the raw materialsJune 30, 2017, nor were at arms-length.there any asserted or unasserted material claims for which material losses are reasonably possible.

 

NOTE 1916 – SUBSEQUENT EVENTS

 

Securities Purchase Agreement - September 30, 2016Certificate of Amendment to the Certificate of Designation of the Company’s Series B Preferred Stock

 

On SeptemberJuly 26, 2017, the Company filed a Certificate of Amendment to the Certificate of Designation of the Company’s Series B Preferred Stock (the “Amendment”) with the Secretary of State of the State of Nevada to provide for an adjustment of the Conversion Rate of the Company’s Series B Preferred Stock in the event of a reverse stock split or combination in the same ratio as the Company’s common stock. A copy of the Amendment was filed as Exhibit 3.14 to the Company’s Current Report on Form 8-K dated July 26, 2017.

Put on Equity Financing Facility

Subsequent to June 30, 2016, we entered into a Securities Purchase Agreement (the “Purchase Agreement 1”)2017, the Company sold 5,519,660 shares of common stock for the net amount of $1,250,000 pursuant to an equity financing facility with an accredited investor (the “Purchaser 1”) pursuant to which we sold to the Purchaser 1 a 12% Senior Convertible Promissory Note due March 31, 2018 (the “Note 1”) in the principal amount of $3,377,500 for a purchase price of $3,377,500 (the “Offering 1”). We received $3,367,500 in net proceeds from the Offering 1 after deducting fees and expenses. The Note 1 and the shares of our common stock, par value $0.001 per share (the “Common Stock 1”) issuable upon conversion of the Note 1 (the “Conversion Shares 1”) are collectively referred to herein as the “Securities 1.”investor.

 

The Purchase Agreement 1 contains customary representations, warranties, and covenants by, among, and for the benefit of the parties.

Pursuant to the Purchase Agreement 1, we agreed to register the Conversion Shares 1 for issuance to the Purchaser 1. On October 4, 2016, we registered the Conversion Shares 1 pursuant to a prospectus supplement filed with the SEC pursuant to our effective shelf registration statement on Form S-3 (Registration No. 333-210673), declared effective by the SEC on August 12, 2016.

12% Senior Convertible Promissory Note

The Note matures on March 31, 2018 (the “Maturity Date”), less any amounts converted or redeemed prior to the Maturity Date. The Note accrues interest at a rate of 12% per annum, payable on the Maturity Date or upon any conversion, prepayment, event of default or other acceleration of payment under the Note. All interest payments under the Note are payable, at our option, in cash or shares of Common Stock.

All principal and interest due and owing under the Note is convertible into shares of Common Stock at any time at the election of the holder at a conversion price per share equal to the lower of (i) $0.35 or (ii) 75% of the average of the three (3) lowest daily volume weighted-average prices of the Common Stock in the fifteen (15) trading days prior to the conversion date (the “Conversion Price”), which Conversion Price is subject to adjustment for (i) stock splits, stock dividends, combinations, or similar events and (ii) full ratchet anti-dilution protection. Upon certain events of default, the conversion price of the Note will automatically become 70% of the average of the three (3) lowest volume weighted average prices of the Common Stock in the twenty (20) consecutive trading days prior to the conversion date for so long as such event of default remains in effect.

In addition, at any time that (i) the daily volume weighted average price of the Common Stock for the prior ten (10) consecutive trading days is $0.70 or more and (ii) the average daily trading value of the Common Stock is greater than $2,500,000 for the prior ten (10) consecutive trading days, then the Company may demand, upon one (1) day’s notice, that the holder convert the Note at the Conversion Price.

We may prepay in cash any portion of the outstanding principal amount of the Note and any accrued and unpaid interest by, upon ten (10) days’ written notice to the holder, paying an amount equal to (i) 110% of the sum of the then-outstanding principal amount of the Note plus accrued but unpaid interest, if the prepayment date is within 90 days of the issuance date of the Note; (ii) 115% of the sum of the then-outstanding principal amount of the Note plus accrued but unpaid interest, if the prepayment date is between 91 days and 180 days of the issuance date of the Note; or (iii) 125% of the sum of the then-outstanding principal amount of the Note plus accrued but unpaid interest, if the prepayment date is after 180 days of the issuance date of the Note.

Securities Purchase Agreement - October 28, 2016

On October 28, 2016, we entered into a Securities Purchase Agreement (the “Purchase Agreement 2”) with an accredited investor (the “Purchaser 2”) pursuant to which we sold to the Purchaser 2 a 12% Senior Convertible Promissory Note due April 28, 2018 (the “Note 2”) in the principal amount of $7,051,000 for a purchase price of $7,051,000 (the “Offering 2”). There were no fees or expenses deducted from the net proceeds received by us in the Offering 2. The Note 2 and the shares of our common stock, par value $0.001 per share (the “Common Stock 2”) issuable upon conversion of the Note 2 (the “Conversion Shares 2”) are collectively referred to herein as the “Securities 2.”

The Purchase Agreement 2 contains customary representations, warranties, and covenants by, among, and for the benefit of the parties.

Pursuant to the Purchase Agreement 2, we agreed to sell the Securities 2 pursuant to an effective shelf registration statement on Form S-3 (Registration No 333-210673), declared effective by the SEC on August 12, 2016, and a related prospectus supplement thereto.


32
Table of Contents

TERRA TECH CORP. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements (Unaudited)

Three and Nine Months Ended September 30, 2016 and 2015

NOTE 19 – SUBSEQUENT EVENTS (Continued)

12% Senior Convertible Promissory Note

The Note matures on April 28, 2018 (the “Maturity Date”), less any amounts converted or redeemed prior to the Maturity Date. The Note accrues interest at a rate of 12% per annum, payable on the Maturity Date or upon any conversion, prepayment, event of default or other acceleration of payment under the Note. All interest payments under the Note are payable, at the Company’s option, in cash or shares of Common Stock.

All principal and interest due and owing under the Note is convertible into shares of Common Stock at any time at the election of the holder at a conversion price per share equal to the lower of (i) $0.41 or (ii) 83.5% of the average of the three (3) lowest daily volume weighted average prices of the Common Stock in the fifteen (15) trading days prior to the conversion date (the “Conversion Price”), which Conversion Price is subject to adjustment for (i) stock splits, stock dividends, combinations, or similar events and (ii) full ratchet anti-dilution protection. Upon certain events of default, the conversion price of the Note will automatically become 70% of the average of the three (3) lowest volume weighted average prices of the Common Stock in the twenty (20) consecutive trading days prior to the conversion date for so long as such event of default remains in effect.

In addition, at any time that (i) the daily volume weighted average price of the Common Stock for the prior ten (10) consecutive trading days is $0.70 or more and (ii) the average daily trading value of the Common Stock is greater than $2,500,000 for the prior ten (10) consecutive trading days, then the Company may demand, upon one (1) day’s notice, that the holder convert the Note at the Conversion Price.

The Company may prepay in cash any portion of the outstanding principal amount of the Note and any accrued and unpaid interest by, upon ten (10) days' written notice to the holder, paying an amount equal to (i) 110% of the sum of the then-outstanding principal amount of the Note plus accrued but unpaid interest, if the prepayment date is within 90 days of the issuance date of the Note; (ii) 115% of the sum of the then-outstanding principal amount of the Note plus accrued but unpaid interest, if the prepayment date is between 91 days and 180 days of the issuance date of the Note; or (iii) 125% of the sum of the then-outstanding principal amount of the Note plus accrued but unpaid interest, if the prepayment date is after 180 days of the issuance date of the Note.

Debt and Interest Converted into Equity

 

During the fourth quarter of 2016,Subsequent to June 30, 2017, senior secured convertible promissory notes and accrued interest in the amount of $9,345,108 was$2,092,492 were converted into 31,281,00615,738,463 shares of common stock.


Employee Stock-Based Compensation

Subsequent to June 30, 2017, the Company issued 117,648 shares of common stock for employee stock-based compensation.

 
33
25
Table of Contents

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

FORWARD-LOOKING STATEMENTS

 

In addition to historical information, this Quarterly Report on Form 10-Q may contain “forward-looking statement”statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which provides a “safe harbor” for forward-looking statements made by us. All statements, other than statements of historical facts, including statements concerning our plans, objectives, goals, beliefs, business strategies, future events, business conditions, results of operations, financial position, business outlook, business trends, and other information, may be forward-looking statements. Words such as “might,” “will,” “may,” “should,” “estimates,” “expects,” “continues,” “contemplates,” “anticipates,” “projects,” “plans,” “potential,” “predicts,” “intends,” “believes,” “forecasts,” “future,” and variations of such words or similar expressions are intended to identify forward-looking statements. The forward-looking statements are not historical facts, and are based upon our current expectations, beliefs, estimates and projections, and various assumptions, many of which, by their nature, are inherently uncertain and beyond our control. Our expectations, beliefs, estimates, and projections are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that management’s expectations, beliefs, estimates, and projections will occur or be achieved and actual results may vary materially from what is expressed in or indicated by the forward-looking statements.

 

There are a number of risks, uncertainties, and other important factors, many of which are beyond our control, that could cause actual results to differ materially from the forward-looking statements contained in this Quarterly Report on Form 10-Q. Such risks, uncertainties, and other important factors that could cause actual results to differ include, among others, the risk, uncertainties and factors set forth under “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2015,2016, filed with the Securities and Exchange Commission (the “SEC”), and in this report, as such risk factors may be updated from time to time in our periodic filings with the SEC, which are accessible on the SEC’s website at www.sec.gov.

 

We caution you that the risks, uncertainties, and other factors set forth in our periodic filings with the SEC may not contain all of the risks, uncertainties, and other factors that are important to you. In addition, we cannot assure you that we will realize the results, benefits, or developments that we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in the way expected. There can be no assurance that: (i) we have correctly measured or identified all of the factors affecting our business or the extent of these factors’ likely impact, (ii) the available information with respect to these factors on which such analysis is based is complete or accurate, (iii) such analysis is correct, or (iv) our strategy, which is based in part on this analysis, will be successful. All forward-looking statements in this report apply only as of the date of the report or as of the date they were made and, except as required by applicable law, we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise.

 

COMPANY OVERVIEW

 

We were incorporated in Nevada on July 22, 2008 under the name Private Secretary, Inc. We changed our name to Terra Tech Corp. on January 27, 2012. is a holding company with the following subsidiaries:

·Edible Garden Corp., a Nevada corporation (“Edible Garden”);

·MediFarm, LLC, a Nevada limited liability company (“MediFarm”);

·MediFarm I, LLC, a Nevada limited liability company (“MediFarm I”);

·MediFarm I Real Estate, LLC, a Nevada limited liability company (“MediFarm I RE”);

·MediFarm II, LLC, a Nevada limited liability company (“MediFarm II”);

·IVXX, LLC, a Nevada limited liability company (“IVXX LLC”);

·IVXX, Inc., a California corporation (“IVXX Inc.”; together with IVXX LLC, “IVXX”);

·Blüm San Leandro, a California corporation (“Blüm San Leandro”);

·Black Oak Gallery, a California corporation (“Black Oak”);

·GrowOp Technology Ltd., a Nevada corporation (“GrowOp Technology”); and

·EG Transportation, LLC, a Nevada limited liability company (“EG Transportation”).

26
Table of Contents

Our corporate headquarters is located at 4700 Von Karman Avenue,2040 Main Street, Suite 110, Newport Beach,225, Irvine, California 9266092614 and our telephone number is (855) 447-6967. Our website addresses are as follows: www.terratechcorp.com, www.growopltd.com, www.ediblegarden.com, www.egrow.com, www.goodearthhydro.com, www.bestbuyhydro.com,www.blumoak.com, www.letsblum.com, www.ivxx.com, and www.ivxx.com.www.ediblegarden.com. No information available on or through our websites shall be deemed to be incorporated into this Quarterly Report on Form 10-Q. Our common stock, par value $0.001 (the “Common Stock”), is quoted on the OTC Markets Group, Inc.’s OTCQX tier under the symbol “TRTC.”

History and Background

 

Our original business was to developdeveloping a software program that would allow for automatic call processing through voice-over-Internet protocol, or “VoIP”, technology. Our operations were limited to capital formation, organization, and development of our business plan and target customer market. We generated no revenue.


34
Table of Contents

 

On February 9, 2012, we completed a reverse-triangular merger with GrowOp Technology Ltd., a Nevada corporation (“GrowOp Technology”), whereby we acquired all of the issued and outstanding shares of GrowOp Technology and in exchange we issued: (i) 33,998,520 shares of our common stock, (ii) 100 shares of Series A Preferred Stock, convertible into shares of common stock on a one-for-one basis, and (iii) 14,750,000 shares of Series B Preferred Stock, with each share convertible into 5.38425537 shares of common stock. The issuance represented approximately 50.3% of our total shares of common stock outstanding, assuming the conversion of all the shares of Series A Preferred Stock and Series B Preferred Stock, immediately following the closing of the merger.Technology. As a result of the merger, GrowOp Technology became our wholly-owned subsidiary. Following the merger, we ceased our prior operations and are now solely a holding company with twoseven wholly-owned subsidiaries. We also own interests in threefour other subsidiaries. Through GrowOp Technology, we engage in the design, marketing, and sale of hydroponic equipment with propriety technology to create sustainable solutions for the cultivation of indoor agriculture.

Our Business

 

We entered intoare a Share Exchange Agreement, dated March 23, 2013vertically integrated cannabis-focused agriculture company that is committed to cultivating and providing the highest quality medical cannabis, as well as other agricultural products, such as herbs and leafy greens that are grown using classic Dutch hydroponic farming methods.

Through Black Oak, we operate a medical marijuana retail dispensary, a medical marijuana cultivation, and have a second medical marijuana cultivation facility under construction (the “Share Exchange Agreement”“Hegenberger facility”), byall in Oakland, California. Through MediFarm, MediFarm I, and amongMediFarm II (together “MediFarm”), we operate four retail medical marijuana dispensary facilities in Nevada, and have in various stages of construction medical marijuana cultivation and production facilities in Nevada. Through MediFarm I RE, we own the Company, Edible Garden Corp.,real property in Nevada on which we plan to build a Nevada corporation (“Edible Garden”), andmedical marijuana dispensary of which we are in the stockholders of Edible Garden. Pursuant to the Share Exchange Agreement, we offered and sold 1,250,000 shares of common stock of the Company in consideration for all the issued and outstanding shares in Edible Garden. Separately, Amy Almsteier, oneplanning phase. All of our stockholdersretail dispensaries in California and Nevada operate under the name Blüm, which offer a director (and, at that time, an officer)broad selection of ours, offeredmedical cannabis products including flowers, concentrates and sold 7,650,000 sharesedibles. Through IVXX, we produce and sell a line of Series B Preferred Stock to Ken Vande Vrede, Mike Vande Vrede, Steve Vande Vrede, Dan Vande Vrede, Beverly Willekes,medical cannabis flowers, as well as a line of medical cannabis-extracted products, which include concentrates, cartridges, vape pens and David Vande Vrede (the “Former EG Principal Stockholders”). The 7,650,000 shares of Series B Preferred Stock are convertible at any time into 36,344,198 shares of common stock and have voting power equal to 765,000,000 shares of common stock.

The effect of the issuance of the 1,250,000 shares of common stock of the company and the sale of the 7,650,000 shares of Series B Preferred Stock by Ms. Almsteier was that as of the date of the issuance and sale, the Former EG Principal Stockholders held approximately 25.7% of the issued and outstanding shares of common stock of the Company and approximately 43.3% of the voting power of the Company. Articles of Exchange, consummating the share exchange, were filed with the Secretary of the State of Nevada on April 24, 2013.wax products. Through Edible Garden, we are thea retail seller of locally grown hydroponic produce.produce, herbs and floral products, which are distributed through major grocery stores such as ShopRite, Walmart, Winn-Dixie, Raley’s, Meijer, Kroger, and others throughout New Jersey, New York, Delaware, Maryland, Connecticut, Pennsylvania and the Midwest. EG Transportation is a company in good standing and no operations to date.

We have a “rollup” growth strategy, which includes the following components:

·With our brand recognition and experienced management team, maximize productivity, provide economies of scale, and increase profitability through our public market vehicle;

·Acquire unique products and niche players where barriers to entry are high and margins are robust, providing them with a broader outlet for their products; and

·Acquire multiple production facilities to capture the market vertical from manufacturing to production up to retail.

Marijuana Industry Overview

Marijuana cultivation refers to the planting, tending, improving and harvesting of the flowering plant Cannabis, primarily for the production and consumption of cannabis flowers, often referred to as “buds”. The cultivation techniques for marijuana cultivation differ than for other purposes such as hemp production and generally references to marijuana cultivation and production do not include hemp.

27
Table of Contents

Cannabis belongs to the genus Cannabis in the family Cannabaceae and for the purposes of production and consumption, includes three species, C. sativa (“Sativa”), C. indica (“Indica”), and C. ruderalis (“Ruderalis”). Sativa and Indica generally grow tall with some varieties reaching approximately four meters. The females produce flowers rich in tetrahydrocannabinol (“THC”). Ruderalis is a short plant and produces trace amounts of THC, but is very rich in cannabidiol (“CBD”) and which is an antagonist (inhibits the physiological action) to THC.

As of May 2017, there are a total of 29 states, plus the District of Columbia, with legislation passed as it relates to medicinal cannabis. These state laws are in direct conflict with the United States Federal Controlled Substances Act (21 U.S.C. § 811) (“CSA”), which places controlled substances, including cannabis, in a schedule. Cannabis is classified as a Schedule I drug, which is viewed as having a high potential for abuse, has no currently-accepted use for medical treatment in the U.S., and lacks acceptable safety for use under medical supervision.

These 29 states, and the District of Columbia, have adopted laws that exempt patients who use medicinal cannabis under a physician’s supervision from state criminal penalties. These are collectively referred to as the states that have de-criminalized medicinal cannabis, although there is a subtle difference between de-criminalization and legalization, and each state’s laws are different.

The states that have legalized medicinal cannabis are as follows (in alphabetical order):

1. Alaska

11. Maine

21. New York

2. Arizona

12. Maryland

22. North Dakota

3. Arkansas

13. Massachusetts

23. Ohio

4. California

14. Michigan

24. Oregon

5. Colorado

15. Minnesota

25. Pennsylvania

6. Connecticut

16. Montana

26. Rhode Island

7. Delaware

17. Nevada

27. Vermont

8. Florida

18. New Hampshire

28. Washington

9. Hawaii

19. New Jersey

29. West Virginia

10. Illinois

20. New Mexico

Medical cannabis decriminalization is generally referred to as the removal of all criminal penalties for the private possession and use of cannabis by adults, including cultivation for personal use and casual, nonprofit transfers of small amounts. Legalization is generally referred to as the development of a legally controlled market for cannabis, where consumers purchase from a safe, legal, and regulated source.

The dichotomy between federal and state laws has also limited the access to banking and other financial services by marijuana businesses. Recently the U.S. Department of Justice and the U.S. Department of Treasury issued guidance for banks considering conducting business with marijuana dispensaries in states where those businesses are legal, pursuant to which banks must now file a Marijuana Limited Suspicious Activity Report that states the marijuana business is following the government’s guidelines with regard to revenue that is generated exclusively from legal sales. However, since the same guidance noted that banks could still face prosecution if they provide financial services to marijuana businesses, it has led to the widespread refusal of the banking industry to offer banking services to marijuana businesses operating within state and local laws.

28
Table of Contents

In November 2016, California and Nevada voters both approved marijuana use for adults over the age of 21 without a physician’s prescription or recommendation, so called recreational marijuana, and permitted the cultivation and sale of marijuana, in each case subject to certain limitations. We have obtained the necessary permits and licenses to expand our existing business to cultivate and distribute marijuana in compliance with the laws in the state of Nevada and California. We have received provisional permits to operate a dispensary and production facility in the city of San Leandro, California, and upon project completion and inspection, to receive final operating permits. Although, there is no guarantee that we will be successful in doing so. Despite the changes in state laws, marijuana remains illegal under federal law.

In November 2016, California voters approved Proposition 64, which is also known as the Adult Use of Marijuana Act (“the AUMA”), in a ballot initiative. Among other things, the AUMA makes it legal for adults over the age of 21 to use marijuana and to possess up to 28.5 grams of marijuana flowers and 8 grams of marijuana concentrates. Individuals are also permitted to grow up to six marijuana plants for personal use. In addition, the AUMA establishes a licensing system for businesses to, among other things, cultivate, process and distribute marijuana products under certain conditions. Many of the provisions of the AUMA do not become effective until January 1, 2018 and the California Bureau of Marijuana Control is expected to enact regulations to implement the AUMA by that date.

Nevada voters approved Question 2 in a ballot initiative in November 2016. Among other things, Question 2 makes it legal for adults over the age of 21 to use marijuana and to possess up to one ounce of marijuana flowers and one-eighth of an ounce of marijuana concentrates. Individuals are also permitted to grow up to six marijuana plants for personal use. In addition, Question 2 authorizes businesses to cultivate, process and distribute marijuana products under certain conditions. On June 30, 2017, the State of Nevada Department of Taxation approved our Dual Use Marijuana business licenses. This approval allowed all four of our Blüm cannabis dispensaries in Nevada to commence sales of cannabis for adult-use beginning on July 1, 2017.

In an effort to provide guidance to federal law enforcement, the Department of Justice (the “DOJ”) has issued Guidance Regarding Marijuana Enforcement to all United States Attorneys in a memorandum from Deputy Attorney General David Ogden on October 19, 2009, in a memorandum from Deputy Attorney General James Cole on June 29, 2011 and in a memorandum from Deputy Attorney General James Cole on August 29, 2013. Each memorandum provides that the DOJ is committed to the enforcement of the CSA, but the DOJ is also committed to using its limited investigative and prosecutorial resources to address the most significant threats in the most effective, consistent, and rational way.

The August 29, 2013 memorandum provides updated guidance to federal prosecutors concerning marijuana enforcement in light of state laws legalizing medical and recreational marijuana possession in small amounts. The memorandum sets forth certain enforcement priorities that are important to the federal government:

·Distribution of marijuana to children;

·Revenue from the sale of marijuana going to criminals;

·Diversion of medical marijuana from states where it is legal to states where it is not;

·Using state authorized marijuana activity as a pretext of other illegal drug activity;

·Preventing violence in the cultivation and distribution of marijuana;

·Preventing drugged driving;

·Growing marijuana on federal property; and

·Preventing possession or use of marijuana on federal property.

The DOJ has not historically devoted resources to prosecuting individuals whose conduct is limited to possession of small amounts of marijuana for use on private property, but has relied on state and local law enforcement to address marijuana activity. In the event the DOJ reverses its stated policy and begins strict enforcement of the CSA in states that have laws legalizing medical marijuana and recreational marijuana in small amounts, there may be a direct and adverse impact to our business and our revenue and profits.

Furthermore, H.R. 83, enacted by Congress on December 16, 2014, provides that none of the funds made available to the DOJ pursuant to the 2015 Consolidated and Further Continuing Appropriations Act may be used to prevent certain states, including Nevada and California, from implementing their own laws that authorized the use, distribution, possession, or cultivation of medical marijuana.

We are monitoring the Trump administration’s, the DOJ’s and Congress’ positions on federal marijuana law and policy. Based on public statements and reports, we understand that certain aspects of those laws and policies are currently under review, but no official changes have been announced. It is possible that certain changes to existing laws or policies could have a negative effect on our business and results of operations.

29
Table of Contents

We currently operate medical marijuana businesses in California and Nevada. Although the possession, cultivation and distribution of marijuana for medical use is permitted in California and Nevada, provided compliance with applicable state and local laws, rules, and regulations, marijuana is illegal under federal law. We believe we operate our business in compliance with applicable Nevada and California law and regulations. Any changes in federal, state or local law enforcement regarding marijuana may affect our ability to operate our business. Strict enforcement of federal law regarding marijuana would likely result in the inability to proceed with our business plans, could expose us to potential criminal liability and could subject our properties to civil forfeiture. Any changes in banking, insurance or other business services may also affect our ability to operate our business.

Our Medical Marijuana Dispensaries, Cultivation and Manufacturing

Black Oak Gallery

On April 1, 2016, we acquired Black Oak, which operates a medical marijuana dispensary in Oakland, California under the name Blüm. Black Oak opened its retail storefront in Oakland, California in November 2012.

Black Oak sells a combination of our own cultivated products as well as high quality name-brand products from outside suppliers. In addition to multiple grades of medical marijuana, Black Oak sells “edibles”, which include cannabis-infused baked goods, chocolates, and candies; cannabis-infused topical products, such as lotions, massage oils and balms; clones of marijuana plants; and numerous kinds of cannabis concentrates, such as hash, shatter and wax.

Black Oak’s target markets are those individuals located in the areas surrounding its dispensary and qualify as “patients” under state and local rules and regulations. Black Oak services approximately 1,000 patients per day and has over 42,000 registered patients. Collectively known as the Blüm Campus, Black Oak’s location consists of a retail dispensary storefront, indoor cultivation area, laboratory and a 20-car capacity parking lot.

During March 2017, we executed a lease for 13,000 square feet of industrial space on over 30,000 square feet of land in Oakland’s industrial corridor. We are in the early stages of construction of the Hegenberger facility. We expect to complete construction by late 2017.

On May 11, 2017, we terminated the Operations and Asset Management Agreement (the “Agreement”) by and among the Company, Black Oak and Platinum Standard, LLC (“Platinum”), dated March 31, 2016. There is no relationship between the Company or its affiliates and Platinum, other than pursuant to the Agreement. Pursuant to the Agreement, the Company hired and appointed Platinum as the operator and asset manager of the Company’s licensed medical cannabis dispensary business located at 578 West Grand Avenue, in the City of Oakland, State of California, commonly known as Blüm Oakland, in exchange for certain payments to be made by the Company to Platinum, all as more fully set forth in the Agreement. We terminated the Agreement as a result of the default by Platinum in the performance of certain of its material obligations under the Agreement. We did not incur any early termination penalty in connection with terminating the Agreement. A copy of the Agreement was filed as Exhibit 10.29 to the Company’s Form 10-Q for the quarterly period ended March 31, 2016. See “Note 9 – Contingent Consideration Liability” for further information.

Blüm San Leandro

We incorporated Blüm San Leandro, a California corporation, a wholly-owned subsidiary, on October 14, 2016. Blüm San Leandro has received the necessary governmental approvals and permitting to operate a medical marijuana dispensary and production facility in San Leandro, California. We have executed a lease for 13,300 square feet of industrial space in San Leandro’s industrial corridor and are in the final planning and design stages of the retail dispensary and production facility. We also plan on incorporating community meeting space at this facility. We expect to complete construction of the dispensary by late 2017 and we expect to complete construction of the production facility and community meeting space by early 2018.

30
Table of Contents

MediFarm, MediFarm I, and MediFarm II

We formed three subsidiaries for the purposes of cultivation or production of medical marijuana and/or operation of dispensary facilities in various locations in Nevada. MediFarm, MediFarm I, and MediFarm II have received four final dispensary licenses, two provisional cultivation licenses and two provisional production licenses from the State of Nevada, and we have received approval from local authorities with respect to all eight of such licenses. The receipt of both the provisional licenses from the State of Nevada and approval from local authorities were necessary to commence the final permitting process for the cultivation and production licenses. The receipt of final permits and licenses was necessary to commence the cultivation and production businesses of MediFarm, MediFarm I, and MediFarm II. Effectuation of the businesses of each of (i) MediFarm, (ii) MediFarm I, and (iii) MediFarm II is also dependent upon the continued legislative authorization of medical marijuana at the state level.

Each subsidiary was formed with different investors, thus necessitating the need for multiple entities with different strategic partners and advisory board members. In addition, we anticipate each subsidiary will service a different geographical market in Nevada. We expect to allocate future business opportunities among MediFarm, MediFarm I, and MediFarm II based on the locations of such opportunities.

 

We formed MediFarm, LLC a Nevada limited liability company (“MediFarm”) on March 19, 2014. We own 60% of the membership interests in MediFarm. The remaining membership interests are owned by Camden Goorjian (20%) and by Richard Vonfeldt (20%), two otherwise unaffiliated individuals. Upon receipt ofMediFarm has received the necessary governmental approvals and permitting as to which there can be no assurance, we expect MediFarm to operate medical marijuana cultivation, production, andand/or dispensary facilities in Clark County, Nevada and a medical marijuana dispensary facility in the City of Las Vegas. As of June 30, 2017, MediFarm has three fully operational retail medical marijuana dispensaries in the greater Las Vegas region.

 

We formed MediFarm I, LLC a Nevada limited liability company (“MediFarm I”) on July 18, 2014. We own 50% of the membership interests in MediFarm I. The remaining membership interests are owned by Forever Green NV, LLC (50%), an otherwise unaffiliated entity. Upon receipt ofentity that also owns certain membership interests in MediFarm II. MediFarm I has the necessary governmental approvals and permitting as to which there can be no assurance, we expectoperate a medical marijuana dispensary in Reno, Nevada. As of June 30, 2017, MediFarm I to operate ahas one fully operational retail medical marijuana dispensary in Reno, Nevada.

 

We formed MediFarm II, LLC a Nevada limited liability company (“MediFarm II”) on July 30, 2014. We own 55% of the membership interests in MediFarm II. The remaining membership interests are owned by Nevada MF, LLC (30%) and by Forever Green NV, LLC (15%), two otherwise unaffiliated parties. Upon receiptentities. Forever Green NV, LLC also owns certain membership interests in MediFarm I. MediFarm II has received provisional licenses from the State of the necessary governmental approval and permitting, as to which there can be no assurance, we expect MediFarm IINevada to operate a medical marijuana cultivation and production facility in Spanish Springs, Nevada.

 

MediFarm, MediFarm I, and MediFarm II may face substantial competition in the operation of cultivation, production, and dispensary facilities in Nevada. Numerous other companies were also granted licenses, and, therefore, we anticipate that we will face competition with these other companies if such companies operate cultivation, production, and dispensary facilities in and around the locations at which we operate our facilities. Our management has extensive experience in successfully developing, implementing, and operating all facets of equivalent businesses in other markets. We formed believe this experience will provide MediFarm, MediFarm I, and MediFarm II with a competitive advantage over these other companies.

MediFarm, MediFarm I, and MediFarm II rely on a combination of trademark laws, trade secrets, confidentiality provisions, and other contractual provisions to protect their proprietary rights. MediFarm, MediFarm I, and MediFarm II do not own any patents.

IVXX LLC, a Nevada limited liability company (“IVXX”) onand IVXX Branded Products

On September 16, 2014, Terra Tech formed IVXX, a wholly-owned subsidiary, for the purposepurposes of producing a line of IVXX branded cannabis flowers and cigarettes, as well as a complete line of IVXX branded pure cannabis pure concentrates including: oils, waxes, shatters, and clears. We currently offer these products

31
Table of Contents

The science of cannabis concentrate extraction functions on the solubility of the cannabinoids and other active ingredients in the cannabis plant. Cannabinoids are not water soluble, so to 200 select dispensariesextract them properly, the cannabinoids must be dissolved in a solvent. IVXX utilizes multiple proprietary extraction methods to produce its concentrates in its lab located in Oakland, California. The Company’s extractors process raw cannabis plants and separate the chemical cannabinoids from the cannabis plant material, producing a concentrate. IVXX also sells clothing, apparel, and other various branded products.


35
Table of Contents

IVXX currently sells its branded products at wholesale to multiple medical cannabis dispensaries throughout California. None of IVXX’s products cross state lines. IVXX continues to actively seek opportunities to sell its products to other retailers located throughout the State of California. IVXX anticipates expanding its business into other states in which the sale of marijuana is legally permitted. In order for such expansion to occur, IVXX must secure the necessary licenses and permits required to operate in any given state, the timing and occurrence of which there can be no assurance. Initially, IVXX anticipates selling its products in Nevada in the four dispensaries operated by MediFarm and MediFarm I. They will be produced at our extraction lab operated by MediFarm II once they are issued final permits and commence operations, as to the occurrence of which there can be no assurance.

 

WeIVXX’s target markets are those individuals located in the areas surrounding the dispensaries that sell IVXX’s products and that qualify as “patients” under state and local rules and regulations.

IVXX also intends to produce, market and sell their line of IVXX branded cannabis products in the adult use, recreational cannabis markets in both California and Nevada pursuant to Proposition 64 and Question 2, respectively, which made marijuana consumption legal, with certain restrictions and rules, for adults over the age of 21. IVXX is consistently engaged in research and development with respect to increasing the efficiency of the processes used to produce its products, as well as improving the quality of its products for the benefit of its patients.

On May 24, 2017, we announced the launch of a new “Craft Cultivation” model to expand our cultivation capabilities and the signing of our first “Craft Cultivator” in Northern California. This farm, which is approved for up to one full acre (approximately 44,000 square feet) of cannabis cultivation and uses 22,000 square feet of engineered greenhouse space, is estimated to yield approximately one metric ton of our proprietary high grade “IVXX” cannabis on an annual basis.

MediFarm I RE

On October 14, 2015, we formed MediFarm I Real Estate, LLC, a Nevada limited liability company (“MediFarm I RE”) on October 14, 2015.RE, LLC. We own 50% of the membership interests in MediFarm I RE. The remaining membership interests isare owned by Forever Young Investments, LLC (50%), an otherwise unaffiliated entity. MediFarm I RE is a real estate holding company that owns the real property and a building that is situated on such real property, at which a medical marijuana dispensary facility willis expected to be located. This facility is in the early stages of planning. It is our intention that MediFarm I will operate the medical marijuana dispensary.

 

Our business segments consistHerbs and Produce Products

Edible Garden

Edible Garden was incorporated on April 9, 2013. Edible Garden is a retail seller of hydroponic produce and cannabis products. Our hydroponic produce is locally grown hydroponic produce, herbs, and floral products that is started from seedare distributed throughout the Northeast and is grown in environmentally controlled greenhouses. When harvested, theMidwest United States. Currently, Edible Garden’s products are sold throughat approximately 1,800 retailers targeted tothroughout these markets. Most of the produce and herbs grown by Edible Garden are certified organic. Our target customers are those individuals seeking organic and fresh produce locally grown using environmentally sustainable methods. This segment consists

Pursuant to letter agreements with Gro-Rite Inc., a New Jersey corporation, and Heartland Growers Inc. (collectively the “Farmers”), have agreed to cultivate the various parts of the line of Edible Garden produce to be sold into the retail grocery channel. Pursuant to the terms of the agreements, Edible Garden will manage the marketing and sales, while the Farmers will be responsible for the cultivation, packaging, and shipping of the product for retail sale under the Edible Garden brand. The terms of the agreements are now month-to-month.

32
Table of Contents

There are numerous growers that are available to us, and therefore, we are not limited in the number of growers available nor are we dependent on any one grower. We completed construction of a greenhouse structure in 2014, which can be used to grow plants to satisfy selling demands; however, we may incur additional freight costs to distribute these plants until growers are replaced.

Edible Garden’s businessmain competitors are Shenandoah Growers and operations. Our cannabis products segment consistsSun Aqua Farms. To a lesser extent, Edible Garden competes with Green Giant, Del Monte, Rock Hedge Herbs, and Infinite Herbs. Edible Garden is an up and coming brand that has increased its retailers to approximately 1,800 retail sellers since we acquired Edible Garden in March 2013. Edible Garden believes the following three factors set it apart from its competitors: (1) its branding and marketing displays, which are predominately placed in high traffic areas on its proprietary racks; (2) it uses proprietary strands and seeds for its produce and its methodology for growing such produce; and (3) all of IVXX’s business,its produce is hydroponically grown and sold “alive” (i.e., the produce is sold “rooted”).

Edible Garden relies on a combination of trademark laws, trade secrets, confidentiality provisions, and other contractual provisions to protect its proprietary rights, which are primarily its brand names, marks, and proprietary pods and seeds. Edible Garden owns trademarks, but does not own any patents. Edible Garden signed an exclusive license agreement with Nutrasorb LLC, a spin-off from Rutgers University, to grow and commercialize nutritionally-enhanced lettuce varieties. Under the terms of the agreement, Edible Garden has the right to grow and sell Green and Red Superleaf Lettuce across the North American and European continents as well as Australia. With five times more antioxidants than ordinary lettuce, the proposed business operationsproduce is high in vitamins A and C, magnesium, iron and potassium contents. It also has high levels of MediFarm, MediFarm I,fiber and MediFarm II. IVXX’s cannabischlorogenic acid for superior digestion. These nutritionally-enhanced, proprietary Green and Red Superleaf Lettuces were developed by scientists at Rutgers University following years of intensive research. Edible Garden pays a license fee to Nutrasorb, LLC for each unit sold.

Edible Garden’s produce is Global Food Safety Initiative certified. Edible Garden also obtained certain organic certifications for its products. No other governmental regulations or approvals are needed or affect its business.

Edible Garden’s research and development activities have primarily focused on developing and testing new pods and seeds, as well as different fertilizers, nutrient blends, and lighting.

Our Operations

We are organized into two reportable segments:

·Herbs and Produce Products – Includes herbs and leafy greens that are grown using classic Dutch hydroponic farming methods; and

·Cannabis Dispensary, Cultivation and Production – Includes cannabis-focused retail, cultivation and production.

Herbs and Produce Products

Either independently or in conjunction with third parties, we are a retail seller of locally grown hydroponic herbs, produce, and floral products, which are currently produceddistributed through major grocery stores throughout the East and Midwest regions of the U.S.

Cannabis Dispensary, Cultivation and Production

Either independently or in our lab in California and are sold in select dispensaries throughout California. We plan toconjunction with third parties, we operate medical marijuana retail dispensaries and a medical marijuana cultivation production, andin California. In addition, we operate four retail medical marijuana dispensary facilities in Nevada, through our subsidiaries, MediFarm, MediFarm I, and MediFarm II.have in various stages of construction, medical marijuana cultivation and production facilities in Nevada. We were granted eight provisional permitsown real property in Nevada on which we plan to build a medical marijuana dispensary. All of our retail dispensaries in California and have received approval from the local authorities with respect to eightNevada offer a broad selection of the eight permits. See Note 16, Segment Information, in the Notes to the Consolidated Condensed Financial Statements for information on our net sales, costmedical cannabis products including flowers, concentrates and edibles. We also produce and sell a line of goods sold, selling, generalmedical cannabis flowers, as well as a line of medical cannabis-extracted products, which include concentrates, cartridges, vape pens and administrative expenses, other income (expense), loss from operations, and identifiable assets by segment for the three and nine months ended September 30, 2016 and September 30, 2015. We believe that our ramped up marketing and branding efforts position us to stay on track for annual revenues this year of approximately $20 million.wax products.

33
Table of Contents

 

RESULTS OF OPERATIONS

 

Three Months Ended SeptemberJune 30, 20162017 Compared to Three Months Ended SeptemberJune 30, 20152016

 

Revenues

 

For the three months ended SeptemberJune 30, 2016,2017, we generated revenues of approximately $6.9$7.84 million, compared to approximately $2.0$9.70 million for the three months ended SeptemberJune 30, 2015, an increase2016, a decrease of approximately $4.9$1.86 million or 35819.2 percent. The increasedecrease was primarily due to revenues from floral sales resulting from a contract that expired at December 31, 2016. The floral revenues were $4.40 million for the three months ended June 30, 2016 versus zero for the three months ended June 30, 2017. The decrease was partially offset by increased revenue generated by Edible Garden forby: (i) the sales of its herbs and floral products and Black Oak, GalleryMediFarm and MediFarm I dispensaries; (ii) IVXX from the sale of its cannabis products; and (iii) Edible Garden from the sale of its herbs and produce products. At this stage in our development, revenues are not yet sufficient to cover ongoing operating expenses.

 

Cost of Goods Sold

For the three months ended June 30, 2017, cost of goods sold was $6.34 million, compared to $8.15 million for the three months ended June 30, 2016, a decrease of $1.81 million or 22.2%. The decrease in cost of goods sold was attributable to: (i) a decrease of $4.19 million from the herbs and produce segment, which had $1.33 million and $5.52 million cost of goods sold for the three months ended June 30, 2017 and 2016, respectively; and (ii) an increase of $2.41 million from the cannabis segment, which had $5.01 million and $2.60 million cost of goods sold for the three months ended June 30, 2017 and 2016, respectively. The cannabis segment increase was related to two additional MediFarm dispensaries and one additional MediFarm I dispensary that were open during the three months ended June 30, 2017 versus not being open during the three months ended June 30, 2016. The herbs and produce segment decrease was related to the expiration of the floral product contract.

Gross MarginProfit

 

Our gross profitsprofit for the three months ended SeptemberJune 30, 20162017 was approximately $1.3$1.51 million, compared to a gross profitsprofit of approximately $370,000$1.55 million for the three months ended SeptemberJune 30, 2015, an increase2016, a decrease of approximately $950,000.$41,000 or 2.6 percent. Our gross margin percentage for the three months ended SeptemberJune 30, 20162017 was approximately 1919.2 percent, compared to approximately 1815.9 percent for the three months ended SeptemberJune 30, 2015.2016. The increase in gross margin percentage was attributable to: (i) the cannabis segment, which had $1.04 million and $1.17 million gross profit for the three months ended June 30, 2017 and 2016, respectively, or 17.2 percent and 31.1 percent gross margin for the three months ended June 30, 2017 and 2016, respectively; and (ii) the herbs and produce segment, which had $451,000 and $356,000 gross profit for the three months ended June 30, 2017 and 2016, respectively, or 25.4 percent and 6.1 percent gross margin for the three months ended June 30, 2017 and 2016, respectively. The cannabis segment decrease was related to two additional MediFarm dispensaries and one additional MediFarm I dispensary that were open during the three months ended June 30, 2017 versus not being open during the three months ended June 30, 2016. The cannabis products gross margin percentage decreased due to discounting of the products sold at the new dispensaries in an effort to gain market share. The herbs and produce segment increase was related to the expiration of the floral product contract.


 
36
34
Table of Contents

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses for the three months ended SeptemberJune 30, 20162017 were approximately $6.0$6.03 million, compared to approximately $2.1$5.36 million for the three months ended SeptemberJune 30, 2015,2016, an increase of approximately $3.9 million$665,000 or 28612.4 percent. The increase was primarily due to: (i) an approximately $401,000 increase in amortization expense due to intangible assets acquired in the Black Oak Gallery acquisition (ii) an approximately $304,000 increase in depreciationsalaries for additional farm equipment used by Edible Garden, depreciation incurred at Black Oak Gallery and the assets placed in service at the MediFarm dispensaries; (iii) an approximately $2,262,000 increase in salaries and wages for the staff hired at the Black Oak Gallery and MediFarm dispensaries; (iv) an approximately $430,000 increase in consulting in connection with MediFarm’s, MediFarm I’s, and MediFarm II’s proposed cannabis business in Nevada; (v) an approximately $141,000 increase in security incurred at the Black Oak Gallery and MediFarm dispensaries; (vi) an approximately $98,000 increase in utilities incurred at the Black Oak Gallery and MediFarm dispensaries; (vii) an approximately $98,000 increase in license fees in connection with the MediFarm dispensaries; (viii) an approximately $82,000 in accounting cost incurred to build the infrastructure of the accounting systems; and (ix) an approximately $76,000 in computer systems incurred to build the infrastructure of the MediFarm dispensaries These increases were offset by a reduction in legal fees of approximately $292,000 primarily related to the preparation and filing of registration statements and reviewing of contracts performed in the prior year.Las Vegas, Nevada.

 

Operating Income (Loss)

 

We realized an operating loss of approximately $4.7$4.52 million for the three months ended SeptemberJune 30, 2016,2017, compared to an operating loss of approximately $1.7$3.82 million for the three months ended SeptemberJune 30, 2015,2016, an increase of approximately $3.0 million$706,000 or 27118.5 percent.

 

Other Income (Expense)

 

Other expenseincome for the three months ended SeptemberJune 30, 20162017 was approximately $866,000,$3.62 million, compared to incomeother expense of approximately $258,000$973,000 for the three months ended SeptemberJune 30, 2015,2016, an increase of approximately $607,000 or 335 percent. For$4.59 million. This increase was primarily attributable to: (i) a $4.99 million gain on settlement of contingent consideration related to the Black Oak acquisition (see “Note 9 – Contingent Consideration Liability” for further information); (ii) a $4.43 million loss on fair market valuation of contingent consideration; (iii) an increase in loss on extinguishment of debt of $1.64 million, which was $1.64 million for the three months ended SeptemberJune 30, 2016, we had2017, compared to zero in the prior year period; (iv) an increase in amortization of debt discount of approximately $352,000 compared to $258,000 in the prior year’s period. We had a loss on extinguishment of debt of approximately $0 compared to $264,000 in the prior’s year’s period. We had a loss on issuance of derivatives in the amount of $867,000$298,000, which was $516,000 for the three months ended SeptemberJune 30, 2016,2017, compared to $0$218,000 in the prior year’s period. The increase of approximately $867,000 was due to convertible notes being issued during the third quarter of fiscal 2016. We hadyear period; (v) a decrease in gain (loss) on fair market valuation of derivatives in the amount of $771,000$1.19 million, which was a gain of $987,000 for the three months ended SeptemberJune 30, 2016,2017, compared to a gainloss of approximately $372,000$206,000 in the prior year’s period. Interest expense totaled approximately $160,000year period; and (vi) a decrease in loss from derivatives issued with debt greater than debt carrying value of $488,000, which was zero for the three months ended SeptemberJune 30, 2016,2017, compared to approximately $109,000 for$488,000 in the three months ended September 30, 2015. This increase was due to more debt outstanding during the three months ended September 30, 2016.prior year period.

 

Net Loss Attributable to Terra Tech Corp.

 

We incurred a net loss attributable to Terra Tech Corp. of approximately $5.6$454,000, or $0.00 per share, for the three months ended June 30, 2017, compared to a net loss attributable to Terra Tech Corp. of $4.93 million, or $0.01 per share, for the three months ended SeptemberJune 30, 2016, compared to a net loss of approximately $2.0 million, or $0.01 per share, for the three months ended September 30, 2015.2016. The primary reasons for the increasedecrease were a decrease in net loss wererevenue, an increase in revenue, a decrease in cost of goods sold (as a percentage of revenue), a significant increase in sales,selling, general and administrative expenses, and an increase in gain on settlement of contingent consideration during the three months ended SeptemberJune 30, 20162017, compared to the prior year’s third quarter.year period.

 

Management will continue its efforts to lower operating expenses and increase revenue. We will continue to invest in further expanding our operations and a comprehensive marketing campaign with the goal of accelerating the education of potential clients and promoting our name and our products. Given the fact that most of the operating expenses are fixed or have a quasi-fixed character, management expects that, as revenue increases, those expenses, as a percentage of revenue, will significantly decrease. Nevertheless, there can be no assurance that we will be able to increase our revenues in succeeding quarters.


 
37
35
Table of Contents

 

NineSix Months Ended SeptemberJune 30, 20162017 Compared to NineSix Months Ended SeptemberJune 30, 20152016

 

Revenues

 

For the ninesix months ended SeptemberJune 30, 2016,2017, we generated revenues of approximately $18.2$14.67 million, compared to approximately $7.8$11.25 million for the ninesix months ended SeptemberJune 30, 2015,2016, an increase of approximately $10.4$3.42 million or 23330.4 percent. ThisThe increase was primarily due to revenue generated by Edible Garden forby: (i) the sales of its herbs and floral products and Black Oak, GalleryMediFarm and MediFarm I dispensaries; (ii) IVXX from the sale of its cannabis products.products; and (iii) Edible Garden from the sale of its herbs and produce products; partially offset by a decrease in revenues from floral sales resulting from the expiration of a contract for floral product that expired at December 31, 2016. The floral revenues were $4.79 million for the six months ended June 30, 2016 versus zero for the six months ended June 30, 2017. At this stage in the Company’sour development, revenues are not yet sufficient to cover ongoing operating expenses.

 

Cost of Goods Sold

For the six months ended June 30, 2017, cost of goods sold was $12.80 million, compared to $9.69 million for the six months ended June 30, 2016, an increase of $3.11 million or 32.1%. The increase in cost of goods sold was attributable to: (i) an increase of $7.70 million from the cannabis segment, which had $10.51 million and $2.81 million cost of goods sold for the six months ended June 30, 2017 and 2016, respectively; and (ii) a decrease of $4.54 million from the herbs and produce segment, which had $2.30 million and $6.84 million cost of goods sold for the six months ended June 30, 2017 and 2016, respectively. The cannabis segment increase was related to: (i) a full six months of cost of goods sold for Black Oak during the six months ended June 30, 2017 versus cost of goods sold for only three months of ownership for the six months ended June 30, 2016; and (ii) two additional MediFarm dispensaries and one additional MediFarm I dispensary that were open during the six months ended June 30, 2017 versus not being open during the six months ended June 30, 2016. The herbs and produce segment decrease was related to the expiration of the floral product contract.

Gross MarginProfit

 

Our gross profitsprofit for the ninesix months ended SeptemberJune 30, 20162017 was approximately $3.1$1.87 million, compared to a gross profitsprofit of approximately $861,100$1.56 million for the ninesix months ended SeptemberJune 30, 2015,2016, an increase of approximately $2.2 million$304,000 or 36019.5 percent. Our gross margin percentage for the ninesix months ended SeptemberJune 30, 20162017 was approximately 1712.7 percent, compared to approximately 11.013.9 percent for the six months ended June 30, 2016. The decrease in gross margin percentage was attributable to: (i) the cannabis segment, which had $1.43 million and $1.09 million gross profit for the six months ended June 30, 2017 and 2016, respectively, or 12.0 percent and 28.0 percent gross margin percentage for the ninesix months ended SeptemberJune 30, 2015.2017 and 2016, respectively; and (ii) the herbs and produce segment, which had $399,000 and $437,000 gross profit for the six months ended June 30, 2017 and 2016, respectively, or 14.8 percent and 6.0 percent gross margin for the six months ended June 30, 2017 and 2016, respectively. The cannabis segment increase was related to: (i) a full six months of gross profit for Black Oak during the six months ended June 30, 2017 versus only three months of ownership that contributed to gross profit for the six months ended June 30, 2016; and (ii) two additional MediFarm dispensaries and one additional MediFarm I dispensary that were open and contributed to gross profit for the six months ended June 30, 2017 versus not being open during the six months ended June 30, 2016. The cannabis products gross margin percentage decreased due to discounting of the products sold at the new dispensaries in an effort to gain market share. The herbs and produce segment decrease in gross profit was partially offset by an increase in gross margin was primarily duepercentage related to better margins from Edible Garden as a resultthe expiration of the completed greenhouse facility with high-tech Dutch bucket hydroponic equipment and the sales generated from Black Oak Gallery and IVXX from the sale of its cannabis products.floral products contract.

36
Table of Contents

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses for the ninesix months ended SeptemberJune 30, 20162017 were approximately $13.5$12.42 million, compared to approximately $7.8$7.29 million for the ninesix months ended SeptemberJune 30, 2015, a decrease2016, an increase of approximately $5.7$5.13 million or 17470.4 percent. The increase was primarily due to:to two factors: (i) an approximately $795,000 increase in amortization expense due to intangible assets acquired in the Black Oak Gallery acquisition (ii) an approximately $378,000 increase in depreciation for additional farm equipment used by Edible Garden, depreciation incurred at Black Oak Gallery and the assets placed in service at the MediFarm dispensaries; (iii) an approximately $3,194,000 increase in salaries and wages for operations at the staff hired atMediFarm dispensaries, which includes $1.36 million of stock compensation expense issued to employees during the six months ended June 30, 2017, compared to no stock compensation issued to employees during the six months ended June 30, 2016; and (ii) three additional months of activity for the Black Oak Gallery and MediFarm dispensaries; (iv) an approximately $2,0540,000 increase in consulting in connection with MediFarm’s, MediFarm I’s, and MediFarm II’s proposed cannabis business in Nevada; (v) an approximately $342,000 increase in security incurred at the Black Oak Gallery and MediFarm dispensaries; (vi) an approximately $164,000 increase in utilities incurred at the Black Oak Gallery and MediFarm dispensaries; (vii) an approximately $123,000 increase in license fees in connection with the MediFarm dispensaries; (viii) an approximately $347,000 in accounting cost incurred to build the infrastructure of the accounting systems; and (ix) an approximately $104,000 in computer systems incurred to build the infrastructure of the MediFarm dispensaries These increases were offset by a reduction in legal fees of approximately $816,000 primarily related to the preparation and filing of registration statements and reviewing of contracts performed in the prior year. Lastly, warrant expense decreased over the prior year’s period by approximately $1.15 million primarily due to no warrants issued in the current period.operations acquired on April 1, 2016.

 

Operating Income (Loss)

 

We realized an operating loss of approximately $10.4$10.55 million for the ninesix months ended SeptemberJune 30, 2016,2017, compared to an operating loss of approximately $6.9$5.73 million for the ninesix months ended SeptemberJune 30, 2015.


38
Table of Contents
2016, an increase of $4.82 million or 84.1 percent.

 

Other Income (Expense)

 

Other expense for the ninesix months ended SeptemberJune 30, 2017 was $930,000, compared to $3.20 million for the six months ended June 30, 2016, a decrease of $2.27 million or 71.0 percent. This decrease was approximately $4.1primarily attributable to: (i) a $4.99 million gain on settlement of contingent consideration related to the Black Oak acquisition (see “Note 9 – Contingent Consideration Liability” for further information); (ii) a $4.43 million loss on fair market valuation of contingent consideration; (iii) an increase in loss on extinguishment of debt of $1.76 million, which was $2.68 million for the six months ended June 30, 2017, compared to income of approximately $3,700 for$921,000 in the nine months ended September 30, 2015. For the nine months ended September 30, 2016, we hadprior year period; (iv) an increase in amortization of debt discount of approximately $398,000$814,000, which was $1.13 million for the six months ended June 30, 2017, compared to $524,000$313,000 in the prior year period. We hadperiod; (v) a loss on the extinguishment of debt of approximately $921,000 for the nine months ended September 30, 2016, compared to $264,000decrease in the prior year period. We had a loss on issuance of derivatives of $1,355,000 for the nine months ended September 30, 2016, compared to approximately $561,000 for the nine months ended September 30, 2015, an increase of approximately $794,000 million or 242 percent, due to more convertible notes being issued during the first nine months of fiscal 2016. We had a lossgain (loss) on fair market valuation of derivatives of approximately $596,000$3.96 million, which was a gain of $2.60 million for the ninesix months ended SeptemberJune 30, 2016,2017, compared to a gainloss of approximately $1.8$1.37 million in the prior year period. Interest expense totaled approximately $276,000period; and (vi) a decrease in loss from derivatives issued with debt greater than debt carrying value of $488,000, which was zero for the ninesix months ended SeptemberJune 30, 2016,2017, compared to $427,000 for$488,000 in the nine months ended September 30, 2015. The decrease is due to less debt outstanding during the nine months ended September 30, 2016.prior year period.

 

Net Loss Attributable to Terra Tech Corp.

 

We incurred a net loss attributable to Terra Tech Corp. of approximately $14.6$10.57 million, or $0.04$0.02 per share, for the ninesix months ended SeptemberJune 30, 2016,2017, compared to a net loss attributable to Terra Tech Corp. of approximately $6.8$9.06 million, or $0.03 per share, for the ninesix months ended SeptemberJune 30, 2015.2016. The primary reasons for the increase were a decrease in net loss wererevenue, and an increase in revenue, a decrease in cost of goods sold (as a percentage of revenue), a significant increase in sales,selling, general and administrative expenses during the ninesix months ended SeptemberJune 30, 20162017, compared to the first nine months of 2015.prior year period.

 

Management will continue to make an effortits efforts to lower operating expenses and increase revenue. We will continue to invest in further expanding our operations and a comprehensive marketing campaign with the goal of accelerating the education of potential clients and promoting our name and our products. Given the fact that most of the operating expenses are fixed or have a quasi-fixed character, management expects that, as revenue increases, those expenses, as a percentage of revenue, will significantly decrease. Nevertheless, there can be no assurance that we will be able to increase our revenues in succeeding periods.quarters.

37
Table of Contents

 

DISCLOSURE ABOUT OFF-BALANCE SHEET ARRANGEMENTS

 

We do not have any transactions, agreements or other contractual arrangements that constitute off-balance sheet arrangements.

 

CRITICAL ACCOUNTING POLICIESPOLICIES AND ESTIMATES

 

Our “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section discusses our unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to revenue recognition, accrued expenses, financing operations, and contingencies and litigation. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The most significant accounting estimates inherent in the preparation of our financial statements include estimates as to the appropriate carrying value of certain assets and liabilities which are not readily apparent from other sources. These accounting policies are described in “Note 12 - Summary of Significant Accounting Policies” of the Notes to the unaudited consolidated financial statementsUnaudited Consolidated Financial Statements included in this report.

 
39
Table of Contents

LIQUIDITY AND CAPITAL RESOURCES

 

We have never reported net income. We incurred net losses for the ninesix months ended SeptemberJune 30, 20162017, and have an accumulated deficit of $60.6$83.44 million as of SeptemberJune 30, 2017, compared to an accumulated deficit of $72.87 million at December 31, 2016. As of SeptemberJune 30, 2016,2017, we had working capital of $6.51 million, compared to a working capital deficit of $9.8 million.$9.56 million at December 31, 2016. At SeptemberJune 30, 2016,2017, we had a cash balance of $3.4$9.13 million, compared to a cash balance of $418,000$9.75 million at December 31, 2015.2016.

 

We have not been able to generate sufficient cash from operating activities to fund our ongoing operations. Since our inception, we have raised capital through private sales of preferred stock, common stock, and debt securities. Our future success is dependent upon our ability to achieve profitable operations and generate cash from operating activities. There is no guarantee that we will be able to generate enough revenue and/or raise capital to support our operations.

 

We anticipate requiring additional capital for the commercial development of our subsidiaries. We anticipate weBlack Oak, Blüm San Leandro and the Hegenberger facility, together, will need an additional $10.0require approximately $3.0 million in capital to complete. Construction for the commercialcompletion of the packaging facility for Edible Garden will require approximately $1.2 million. The estimated construction budget for the development of MediFarm, MediFarm I, and MediFarm II. In April 2016, MediFarm commenced operations at its dispensary located in Las Vegas, Nevada under the Blüm brand. None of MediFarm, MediFarm I, or MediFarm II has commenced operations at any other of its proposed cultivation, production, or dispensary facilities.

With respect to the proposed cultivation and production facilities we intend to complete the construction of such facilities in phases, the timing of which will be dictated by market demand. Accordingly, the $13.5 million budget as described hereinunder MediFarm II is entirely prospective as to the timing and amount of expenditures.

With respect to MediFarm, the estimated construction budget (for year one) and operation budget (for the first five years of operation) is $750,000 for the dispensary facilities and $6.0 million for the cultivation and production facility.

With respect to MediFarm I’s dispensary facility, the estimated construction budget (for year one) and operation budget (for the first five years of operation) is $750,000.

With respect to MediFarm II’s cultivation and production facility, the estimated construction budget (for year one) and operation budget (for the first five years of operation) is $6.0approximately $2.0 million.

Forever Green NV, LLC, a member of both MediFarm I and MediFarm II, has agreed to contribute $500,000 in the form of debt to MediFarm I andapproximately $750,000 in the form of debt to MediFarm II. We will be obligated to contribute the remaining amount, or $9.3 million in the aggregate, for all three subsidiaries. This amount is in addition to any proceeds we may receive if and when we sell additional securities.amount.

 

We will be required to raise additional funds through public or private financing, additional collaborative relationships or other arrangements until we are able to raise revenues to a point of positive cash flow. We believe our existing and available capital resources will be sufficient to satisfy our funding requirements through the fourthsecond quarter of 2017.2018. We are evaluating various options to further reduce our cash requirements to operate at a reduced rate, as well as options to raise additional funds, including obtaining loans and selling common stock. There is no guarantee that we will be able to generate enough revenue and/or raise capital to support our operations, or if we are able to raise capital, that it will be available to us on acceptable terms, on an acceptable schedule, or at all.

38
Table of Contents

 

The issuance of additional securities may result in a significant dilution in the equity interests of our current stockholders. Obtaining loans, assuming these loans would be available, will increase our liabilities and future cash commitments. There is no assurance that we will be able to obtain further funds required for our continued operations or that additional financing will be available for use when needed or, if available, that it can be obtained on commercially reasonable terms. If we are not able to obtain the additional financing on a timely basis, we will not be able to meet our other obligations as they become due and we will be forced to scale down or perhaps even cease our operations.


40
Table of Contents

Due to the uncertainty of our ability to meet our current operating and capital expenses, we included a note to our consolidated financial statements for the year ended December 31, 2015 regarding concerns about our ability to continue as a going concern. There is substantial doubt about our ability to continue as a going concern as the continuation and expansion of our business is dependent upon obtaining further financing, successful and sufficient market acceptance of our products, and achieving a profitable level of operations. The unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability or classification of recorded assets and liabilities that might result should we be unable to continue as a going concern.

 

Operating Activities

 

Cash used in operationsoperating activities for the ninesix months ended SeptemberJune 30, 20162017 was $4.6$7.15 million, compared to $3.4$3.30 million for the ninesix months ended SeptemberJune 30, 2015,2016, an increase of $1.2$3.85 million, or 133.7116.4 percent. Increases in cash used in operationsoperating activities were primarily due to: (i) a $7.9$11.48 million net loss for the six months ended June 30, 2017, compared to a $9.32 million loss for the six months ended June 30, 2016, an increase in net loss;of $2.16 million; (ii) a decrease of $1.1 million for warrants issued with common stock and debt in the prior period compared to none in the current period; and (iii) a $1.4 million increase in inventory. Decreases in cash used in operations were primarily due to: (i) a $596,000 lossgain (loss) on fair market valuation of derivatives of $3.96 million, which was a gain of $2.60 million for the ninesix months ended SeptemberJune 30, 2016,2017, compared to a $1.8loss of $1.37 million gainin the prior year period; and (iii) a decrease in accounts payable and accrued expenses of $1.35 million. Decreases in cash used in operating activities were primarily due to: (i) an increase in loss on fair market valuationextinguishment of derivativesdebt of $1.76 million, which was $2.68 million for the ninesix months ended SeptemberJune 30, 2015,2017, compared to $921,000 in the prior year period; and (ii) an increase in amortization of $2.4debt discount of $814,000, which was $1.13 million or 33.5 percent; and (iii) $1.7 million of depreciation and amortization expense for the ninesix months ended SeptemberJune 30, 2016,2017, compared to $481,000 for$313,000 in the nine months ended September 30, 2015, an increase of $1.2 million.prior year period.

 

Investing Activities

 

Cash used in investing activities for the ninesix months ended SeptemberJune 30, 20162017 was $3.1$1.04 million, compared to cash used byin investing activities of $590,000$1.90 million for the ninesix months ended SeptemberJune 30, 2015.2016, a decrease of $864,000, or 45.5 percent. During the first ninesix months of 2016,2017, cash used in investing activities was primarily comprised of expenditures related toto: (i) the construction of the MediFarm dispensariesSan Leandro and Oakland facilities; and (ii) capital expenditures at Edible Garden in Nevada.Belvidere, N.J.

 

Financing Activities

 

Cash provided by financing activities for the ninesix months ended SeptemberJune 30, 20162017 was $10.7$7.57 million, compared to $4.5$6.46 million for the ninesix months ended SeptemberJune 30, 2015,2016, an increase of $6.1$1.11 million, or 23617.2 percent. Cash provided by financing activities for the ninesix months ended SeptemberJune 30, 20162017 was primarily due to $4.9to: (i) $6.00 million from the issuance of debt, $3.2debt; (ii) $3.75 million from the sale of common stock and $3.2stock; partially offset by (iii) payment of $2.09 million for the exercise of warrants into common stock.contingent consideration related to the Black Oak acquisition.

39
Table of Contents

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKRISK.

 

Our primary market risks are attributable to fluctuations in commodity prices and interest rates. These fluctuations can affect revenues and cash flow from operating, investing and financing activities.

Commodity Price Risk

Our most significant market risk relates to fluctuations in marijuana prices. Management expects the prices of these commodities to remain volatile and unpredictable. As these prices decline or rise significantly, revenues and cash flow will also decline or rise significantly.

Interest Rate Risk

As of June 30, 2017, we had no outstanding variable-rate debt and $3.65 million of principal fixed-rate debt.

Credit Risk

Our exposure to non-payment or non-performance by our customers and counterparties presents a smaller reporting company (as definedcredit risk. Generally, non-payment or non-performance results from a customer’s or counterparty’s inability to satisfy obligations. We may also be exposed to credit risk due to the concentration of our customers in Rule 12b-2 of the Exchange Act),medical marijuana industry, as our customers may be similarly affected by changes in regulatory and legal conditions in the states and municipalities in which we are not required to provide the information called for by this Item 3.operate.

 

ITEM 4. CONTROLS AND PROCEDURES.

 

Under the supervision and with the participation of our management, our principal executive officer and our principal financial officer are responsible for conducting an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of the end of the fiscal year covered by this report. Disclosure controls and procedures means that the material information required to be included in our SEC reports is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms relating to our company, including any consolidating subsidiaries, and was made known to us by others within those entities, particularly during the period when this report was being prepared. Based on this evaluation, our principal executive officer and principal financial officer concluded as of the evaluation date that our disclosure controls and procedures were not effective as of SeptemberJune 30, 2015.2017.

 

There were no changes in our internal controls over financial reporting during the most recently completed fiscal quarter that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

 
 
41
40
Table of Contents

 

PART II.II OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS.

 

We are not currently subject to any legal proceedings. From time to time, we may become subject to litigation or proceedings in connection with our business, as either a plaintiff or defendant. There are no such pending legal proceedings to which we are a party that, in the opinion of management, is likely to have a material adverse effect on our business, financial condition or results of operations.

 

ITEM 1A. RISK FACTORS.

 

There have been no material changes to the risk factors disclosed in Part I, Item 1A, “Risk Factors,”“Risk Factors”, of our Annual Report on Form 10-K for the year ended December 31, 2015.2016. Please refer to that section for disclosures regarding the risk and uncertainties relating to our business.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

None.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES.

 

None.

 

ITEM 5. OTHER INFORMATION.

 

None.

 
 
42
41
Table of Contents

 

ITEM 6. EXHIBITS.

 

(a)

Exhibit

Description

3.1

Certificate of Amendment to Certificate of Designation of Series B Preferred Stock, dated July 26, 2017 (1)

4.1

Form of 12% Senior Convertible Promissory Note (2)

4.2

Form of 12% Senior Convertible Promissory Note (3)

10.1

Operations and Asset Management Agreement dated March 31, 2016, by and among Platinum Standard, LLC, Black Oak Gallery, and Terra Tech Corp. (4)

10.2

Form of Security Agreement, dated as of June 23, 2017 (2)

10.3

Form of Security Agreement, dated as of February 22, 2017 (3)

31.1

Certification of Derek Peterson, Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. *

 

31.2

Certification of Michael C. James, Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. *

 

32.1

Certification of Derek Peterson, Chief Executive Officer, pursuant to Sections 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350. *

 

32.2

Certification of Michael C. James, Chief Financial Officer, pursuant to Sections 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350. *

 

101.INS

XBRL Instance Document *

 

101.SCH

XBRL Taxonomy Extension Schema Document *

 

101.CAL

XBRL Taxonomy Extension Calculations Linkbase Document *

 

101.DEF

XBRL Taxonomy Extension Definition Linkbase Document *

 

101.LAB

XBRL Taxonomy Extension Label Linkbase Document *

 

101.PRE

XBRL Taxonomy Presentation Linkbase Document *

______________

* filedFiled herewith


(1)Incorporated by reference to Current Report on Form 8-K filed with the SEC on July 26, 2017.
(2)Incorporated by reference to Current Report on Form 8-K filed with the SEC on June 23, 2017.
(3)Incorporated by reference to Current Report on Form 8-K filed with the SEC on February 22, 2017.
(4)Incorporated by reference to Quarterly Report on Form 10-Q filed with the SEC on May 12, 2016.

 
43
42
Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



 

TERRA TECH CORP.

Date: November 9, 2016August 8, 2017

By:

/s/ Michael C. James

Michael C. James

Chief Financial Officer
Chief Accounting Officer

 

 

4443